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 i   
Abstract 
 
This project sought to perform the in vitro work needed to accomplish the long-
term vision of harnessing the similarities between HIV (Human Immunodeficiency Virus) 
and FIV (Feline Immunodeficiency Virus) to develop an animal model whereby cats can 
be used to study HIV pathogenesis and therapeutics. We transfected CRFK (Crandell 
Rees Feline Kidney) fibroblasts with plasmids that could express human or feline CD4, 
CCR5, or both, and determined receptor surface expression through flow cytometry. We 
discovered that HIV envelope expressed on 293T can fuse with huCD4/huCCR5 on 
CRFK. These cat cell lines were also capable of supporting HIV infection. Additionally, 
we evaluated whether the yeast recombination system could be used to clone FHIVenv 
chimeras wherein the HIV env is inserted into the FIV backbone in place of FIV env. In 
the future, FHIVenv adapted to replicate in the cat cell lines produced herein, can be 
tested in in vivo in cats.  
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ii 
Summary for Lay Audience 
 
The lack of suitable, cost-effective animal models remains a challenge in studying 
HIV (Human Immunodeficiency Virus). Cats are natural hosts for FIV (Feline 
Immunodeficiency Virus), which is similar in structure and pathogenesis to HIV. This 
project’s goal was to establish the in vitro work needed to accomplish the long-term 
vision of utilizing cats in vivo to study HIV therapeutics and vaccines. The in vitro work 
involves creating chimeric viruses as well as engineering the cell lines required for testing 
viral envelope interactions with entry receptors. These viruses and cell lines are also 
required for the infectivity assays. We sought to execute this through the creation of 
FHIVenv chimeras composed of HIV envelope genes inserted into the FIV genome, in 
place of FIV envelope. We attempted several DNA cloning strategies to accomplish this. 
We also engineered CRFK (Crandell Rees Feline Kidney) Fibroblast cell lines to express 
human and feline CD4 and CCR5 and tested the receptor expression level on their 
surface. We were able to achieve higher human CD4/CCR5 expression than feline 
CD4/CCR5 expression on independent CRFK cell lines. Human CD4 and CCR5 are 
typically used by HIV envelope to enter and infect human cells and we found that not 
only can HIV envelope proteins from diverse HIV subtypes and strains bind to human 
CD4 and CCR5 expressed on cat cells, HIV-AD8 (a subtype B virus) can also use these 
receptors to enter and infect cat cells. In the future, receptor-envelope interactions can be 
tested between these diverse HIV envelopes and the engineered feline CD4/CCR5 CRFK. 
The envelopes that are capable of interacting with these feline receptors can be cloned 
into FHIVenvs, following which infectivity assays can be conducted, where the chimeras 
can be used to infect feCD4/feCCR5 CRFK. The eventual goal is to test these chimeras in 
vivo in cats. If they are pathogenic, infectious, and replication-competent in vivo, cats can 
be utilized as model organisms to develop and test therapeutics and vaccine strategies 
targeting the HIV envelope. 
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CHAPTER 1: INTRODUCTION 
1.1 Overview 
 
Worldwide, at the end of 2018, 36.9 million people were living with the Human 
Immunodeficiency Virus (HIV), the majority of whom reside in sub-Saharan Africa. 
Almost one million individuals lost their lives within the same year due to HIV-related 
illnesses1. In Canada, by the end of 2014, 75,500 individuals were living with HIV and/or 
AIDS (Acquired Immune Deficiency Syndrome)2. These statistics reveal that HIV 
continues to be a global healthcare crisis. 
Currently, anti-retroviral therapy (ART) regimens are widely used to control HIV 
replication and plasma viral load. However, these require strict adherence to the ART 
regimen and a lack thereof can promote viremia and increase the development of drug- 
resistant HIV populations3. Furthermore, access to treatment still remains a challenge due 
to stigma, gender disparities where women are disproportionally affected, and 
socioeconomic factors4. These drugs are also prohibitively expensive in developing 
countries5, which is even more problematic as these areas are where populations that are 
most vulnerable to the disease are situated. Due to this, research efforts have shifted to 
create vaccines, and have been undertaken globally to prevent and eradicate the infection. 
Despite these attempts, we do not currently have an effective vaccine to tackle HIV 
infections. Vaccine trials such as RV144 have shown promise6 as the vaccine efficacy 
was close to 60% in the first year of administration. However, this decreased to 31.2% 
over the course of 3.5 years7,8. Therefore, further investigation needs to be undertaken to 
elicit an effective, durable, and long-lasting protective immune response. Thus, it is 
imperative to continue studying novel vaccine strategies. 
A major barrier to generating a successful vaccine against HIV is the lack of ideal 
animal models. Prior studies have exploited animals ranging from rodents, such as 
‘humanized’ mice and rats, to non-human primates including macaques and chimpanzees. 
The major issues with using these organisms are that they are extremely expensive to 
produce, obtain, and house9–11, and inoculation with HIV does not recapitulate the same 
extent of disease observed in humans. 
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Cats, on the other hand, are natural hosts for Feline Immunodeficiency Virus 
(FIV), which is very similar in genomic structure and pathogenesis to HIV12. 
Additionally, they provide a more cost-effective avenue than non-human primates. Our 
long-term vision is to establish a novel animal model that utilizes cats to study HIV 
pathogenesis and vaccine development. If successful, the novel system could be used in 
future to develop and test HIV vaccines using cats as model organisms. This project was 
geared towards generating and evaluating the cell lines and viruses to test the validity of 
this model in vitro.    
1.2 Animal models for HIV research 
1.2.1 Mouse models 
The majority of small animal models have utilized “humanized” mice that are 
genetically immunocompromised and engrafted with human tissue. Variations of severe 
combined immunodeficiency (SCID) mice that lack functional B and T cells have been 
used9,13. One such variation makes use of scid-hu-PBL (hu-PBL-SCID) mice, where scid 
mice are injected with human peripheral blood lymphocytes (PBL), followed by 
intraperitoneal injection with HIV14. These mice can also respond to passive 
immunization with human antibodies, which confer protection upon being challenged 
with HIV-115,16. This makes them good candidates to study the neutralizing antibody 
response during infections. Alternatively, SCID-hu-Thy/Liv mice produced by 
transplanting fetal human thymus and liver cells into SCID mice are capable of producing 
human hematopoietic progenitor stem cells and thymocytes, eventually leading to the 
circulation of human T cells in peripheral blood. When inoculated with HIV, they present 
rapid CD4+ T cell loss and increased viral loads, which is a hallmark of HIV infection in 
humans. Thus, the model can be used to study HIV tropism, cellular pathogenesis, and 
CD4+ T cell loss17. A disadvantage of both these mouse models is that they require direct 
injection of HIV and mucosal transmission cannot be tested9. 
In addition to the two models above, NOD (Non-obese diabetic) scid mice that 
lack NK cells and proper complement activation can also be crossed with IL2rg-/- mice 
that contain a mutation in the interleukin-2 receptor common γ-chain to produce NSG 
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mice (NOD scid gamma) or NOG mice (NOD/Shi-scid IL2rgnull). As the IL2rg protein is 
implicated in immune cell development, crossing IL2rg-/- and NOD scid mice results in 
mice that lack functional immune cells. NOD/SCID/IL2rgnull mice can be transplanted 
with CD34+ hematopoietic stem cells from cord blood, which then produce human B 
cells and T cells18. NSG mice have successfully been infected with HIV and have also 
served as model organisms to test cART (combinational ART) to suppress plasma 
viremia, as well as HIV latency19. 
Bone marrow-liver-thymus (BLT) mice are derived from NOD scid and NSG 
mice that are engrafted with fetal human thymus and liver cells. This is followed by a 
bone marrow graft through the introduction of CD34+ hematopoietic progenitor cells. 
These mice develop a thymus where human thymocytes are educated20. The advantages 
to this model are that T cells mature in the implanted thymus, mimicking T cell 
development in humans, and it is possible to infect them with HIV via mucosal routes9. 
Mouse models are valuable as these organisms are easy to access due to being 
widely available. This allows for larger sample sizes that could produce more reliable 
statistical results. However, these models do not recapitulate a fully functional human 
immune system, making them less reflective of HIV pathogenesis in humans. 
Additionally, the possibility of studying tissue-specific infection and latent reservoirs is 
limited in these models, as human immune cells do not fully engraft in mouse organs. 
Lastly, producing these mice through surgical engraftment and maintaining them is very 
expensive9. 
1.2.2 Non-human primate models: Simian Immunodeficiency Virus (SIV) 
Several different Simian Immunodeficiency Virus (SIV) strains are endemic to 
non-human primates. Phylogenetic analysis has also revealed that HIV-1 is a direct 
descendant of SIVcpz that typically infects the chimpanzee species Pan troglodytes 
troglodytes9,21. HIV-2, on the other hand, is more closely related to SIVsmm isolated from 
sooty mangabeys (Figure 1). 
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Figure 1. Comparison of SIV and HIV genomes. HIV-1 is a descendent of SIVcpz and the 
two share the same structural and accessory genes. HIV-2, SIVsmm and SIVmac are closely 
related and share the same structural and functional genes. HIV-2 lacks the vpu accessory 
gene but instead encodes vpx, another accessory gene. 
 
Upon inoculation with HIV-1, chimpanzees evolve similar symptoms to humans 
infected with this virus. These include the establishment of persistent infection, virus 
presence in peripheral blood, as well as cellular and humoral immune responses directed 
against HIV. Despite this, chimpanzees rarely develop AIDS21. A 1997 study by 
Novembre et al. described the development of AIDS in a chimpanzee infected with HIV-
1. This was associated with the loss of CD4+ T cells, increased plasma viral loads, and 
opportunistic infections. However, this was the case with only one of the twelve 
chimpanzees that were inoculated with several strains of HIV-1 in the mid-1980s. 
Sequence analysis revealed that in the chimpanzee that developed AIDS, there was a 
drastic amount of divergence between the initial inoculation strain and the prevalent 
strain during acute infection. This was indicative of adaptive mutations that occurred in 
the virus over time, which also resulted in increased pathogenicity22. Nevertheless, HIV-
induced pathogenesis and progression to AIDS in HIV-infected chimpanzees is a rare 
occurrence9,22,23 ,which reduces their suitability to serve as model systems for HIV study. 
In addition to this, other logistical reasons including cost, endangered status9,21, and 
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ethical considerations11 pose challenges in utilizing them as model organisms. 
The majority of primate species cannot be infected by HIV-1. Since SIV is closely 
related to HIV, it is instead used widely in studies involving primates to evaluate 
pathogenesis and immune responses upon infection. The advantage of using these 
organisms is that in addition to direct injection, they can be infected through vaginal or 
rectal routes that are comparable to sexual transmission or through oral routes, which 
models maternal transmission via breast milk in humans11. Physiologically, the structure 
of reproductive and gastrointestinal mucosa of macaques and humans are similar and 
serve as important sites for HIV infection and replication. The most common primate 
species used are rhesus macaques (Macaca mulatta), pig-tailed macaques (Macaca 
nemestrina), and cynomolgus macaques (Macaca fascicularis)9. 
SIV infection has several similarities to HIV infection in humans including 
increased viral load and replication, some loss of lymphocytes, and immune activation. 
However, depending on the strain of SIV used, infection is not necessarily fatal. Natural 
macaque hosts do not have progressive loss of CD4+ T cells, chronic immune infection24, 
or total deterioration of lymph nodes9, indicating that these infections do not completely 
mimic HIV infection. There are certain differences between HIV and SIV at the genetic 
and structural level. For example, both SIV and HIV use CD4 (Cluster of Differentiation 
4) as their primary receptors for entry. They also predominantly use CCR5 (C-C 
Chemokine Receptor Type 5) as their co-receptors. However, HIV can also gain the 
ability to utilize CXCR4 (C-X-C Receptor Type 4) as its co-receptor, later in infection; a 
phenomenon rarely seen in SIV infection9. CXCR4 and CCR5 are both G-protein coupled 
receptors that bind chemokines. CCR5 regulates the trafficking and effector functions of 
immature dendritic cells, macrophages, and T lymphocytes25.  The interaction of CXCR4 
with its ligand, CXCL12, is required in hematopoiesis for hematopoietic stem cell 
quiescence, hematopoietic stem cell retention in the bone marrow, and thymocyte 
trafficking in the thymus26. CD4 is primarily expressed on helper T cells and it plays a 
role in T cell signaling27. 
In addition to studying HIV pathogenesis, non-human primate models have also 
been used to study lentiviral vaccines. SIV has served as a vaccine model for several 
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years28,29. In a recent example, Berry et al. (2015) demonstrated that inoculation with live- 
attenuated SIVmacC8 and SIVmacJ5 that are nef-disrupted and nef-intact, respectively, 
can prevent superinfection upon macrophage and neurotropic SIV challenge30. Following 
that, Shin et al. (2018) also constructed replication-incompetent recombinant rhesus 
monkey rhadinovirus containing the near full length SIV genome. Not only did they see 
SIV protein expression upon administration of this recombinant virus in macaques, they 
also observed some level of anti-SIV immune responses31. For their study, Hansen et al. 
(2013) utilized RhCMV/SIV vectors which are cytomegalovirus (CMV) vectors 
containing SIV genes. Macaques that were inoculated with these, followed by pathogenic 
SIVmac239 challenge demonstrated viral dissemination at first. However, over time, viral 
loads decreased. Tissues necropsied several weeks after the challenge had no levels of 
SIV DNA or RNA greater than background32. 
Although various vaccines have demonstrated protection of macaques, there has 
been difficulty in isolating the immune effector variables or markers in vitro that are 
responsible for the protection observed in vivo, making it difficult pinpoint the exact 
mechanism of protection. Variation in host genetics that could contribute to conferring 
protection can also confound these analyses33. Vaccine studies as such require a large 
sample size to find the common host factors that are responsible for the defensive 
mechanism seen in vaccine protected animals. 
The close phylogenetic relationship between humans and non-human primates, as 
well as HIV and SIV make macaques decent candidates for studying HIV pathogenesis 
and vaccine development. HIV and SIV share similar pathology, but they are not 
equivalent when comparing genetic structures. SIVmac and SIVsmm lack the vpu (viral 
protein U) gene seen in HIV-1, and instead have a vpx gene (Figure 1). Although both 
function as antagonists against host restriction factors, Vpu downregulates CD434 and 
antagonizes host tetherin to promote viral progeny release35; whereas, Vpx counteracts 
SAM domain-and-HD domain- containing protein (SAMHD1) to inhibit it from reducing 
the concentration of dNTPs in the cell cytoplasm9. Thus, HIV-1 does not have a known 
mechanism for countering SAMHD1. Additionally, the open reading frames are 
organized differently in HIV-1 and SIVmac/SIVsmm and they only have 53% identity in the 
arrangement of their nucleotides9. Moreover, protective immune responses generated 
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against SIV may not protect against HIV. Consequently, to continue to utilize non-human 
primates as model organisms to study HIV microbicides and for vaccine development, it 
became important to design a virus that was more genetically similar to HIV, but was still 
able to infect and replicate in macaques. This led to the establishment of the Simian-
Human Immunodeficiency (SHIV) model. 
1.2.3 Non-human primate models: Simian Human Immunodeficiency Virus 
(SHIV) 
SHIV is a chimeric virus, created using components of SIV and HIV. Specifically, 
it uses the SIV backbone in which several SIV genes have been replaced with HIV 
counterparts (Figure 2). The benefit of this is that since the chimeric virus contains genes 
belonging to both SIV and HIV, it allows for the establishment of more potent 
microbicides and vaccines targeted at the HIV components, with the advantage of 
continuing to use macaques as the model organisms. 
 
 
 
Figure 2. Representation of chimeric SHIVs composed of the SIV backbone wherein a 
variety of genes are replaced with their HIV counterparts. Blue boxes denote HIV genes. 
Pink boxes denote SIV genes. 
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Early versions of SHIV were comprised of the insertion of HIV env (envelope), 
rev (regulator of expression of viral proteins), tat (trans-activator of transcription), and 
vpu genes into the SIV backbone (Env-SHIV in Figure 2). These versions were unable to 
efficiently replicate and induce disease in macaques initially, but after several passages, 
they achieved replication and infection competence. Infection with these adapted virulent 
strains of SHIV induce rapid CD4+ T cell loss within a few weeks and cause AIDS 
within two years in macaques. They were also able to promote lymphoid and organ-
specific deterioration36–38. 
Another version called RT-SHIV (Figure 2) includes the HIV-1 reverse 
transcriptase (RT) portion of the pol gene., which made it a good candidate to study ART 
drugs that target this enzyme. This was especially important as SIV RT was insensitive to 
non-nucleoside reverse transcriptase inhibitors (NNRTIs)9,33 such as efavirenz. However, 
some mutations seen in SIV and RT-SHIV infection of macaques due to prolonged 
treatment with zidovudine, nevirapine, efavirenz, lamivudine (3TC), emtricitabine (FTC), 
or tenofovir are reminiscent of those seen in HIV-1 and HIV-233. 
The SHIV model has also lent itself to HIV vaccine research. Joag et al. (1998) 
utilized live attenuated vaccines constructed using SHIV deletions. One of these had 
deletions in SHIV vpu, and the other had deletions in SHIV nef and vpu, both of which 
are accessory genes that increase virulence. Upon challenge with pathogenic SHIVKU-1, 
10 out of the 12 macaques that were vaccinated with either of the vaccines had reduced 
viral replication and demonstrated anti-viral immune responses. All the control organisms 
that were not vaccinated experienced CD4+ T cells loss and AIDS onset as early as 12 
weeks after being inoculated with SHIVKU-139. This was a promising avenue for the 
potential of live-attenuated vaccines to confer resistance to HIV infection. More recently, 
Pauthner et al. (2019) demonstrated that macaques with a high titre of neutralizing 
antibodies, produced as a result of immunization with HIV envelope glycoprotein SOSIP 
trimers, showed protection against challenge with SHIVBG50540, a type of Env-SHIV 
described in Li et al. (2016)41. 
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SHIV chimeras have also proved themselves as valuable in studying HIV 
pathogenesis and ART drug efficacy and vaccine strategies using non-human primates, 
primarily macaques, as model organisms. However, even with the replacement of certain 
genes in the SIV backbone with HIV, the chimeric virus infection does not completely 
mimic HIV infection in humans. This serves as a barrier, especially in developing 
vaccines, as they may confer resistance upon infection with the chimeric virus, but may 
be incapable of inducing the same response during HIV infection. 
Apart from this, using non-human primates poses numerous difficulties. In the 
US, there has been a steady decline since 2008 in the number of non-human primates 
being imported from Asia for research purposes10. Lack of non-human primate usage can 
be attributed to economic, logistical, and ethical factors. These organisms are extremely 
expensive to obtain and accommodate, so studies are limited to small population sizes, 
which could reduce the statistical power of results11. In accordance with these reasons, it 
has become imperative to establish other animal models to study and develop HIV 
vaccines and anti-HIV drugs. 
1.3 Feline Immunodeficiency Virus (FIV) 
Feline Immunodeficiency Virus (FIV) was first described in 1987, with infection 
leading to AIDS in cats from which it was isolated42. Its similarity to HIV became 
obvious soon after that, and its potential to serve as a tool for learning more about HIV 
became evident43. 
While many felid species including lions, bobcats, and pumas are infected with 
different species of FIV, only domestic cat FIV infection is known to cause overt 
disease43,44. Natural transmission of FIV occurs mainly through bites during fights or 
mating between cats via exposure to infected blood or blood-contaminated saliva. In 
addition to transmission via mucosal routes, vertical transmission has been reported to 
occur prenatally from infected mother to child, and postnatally though infected milk or 
colostrum45,46. 
Experimentally, cats can be infected with FIV by injection, oral inoculation47, and 
via the intact vaginal or rectal mucosa48,49. 
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Furthermore, various strains of FIV that are pathogenic in vivo, have been 
successfully used to generate molecular clones that are replication-competent in vitro. 
These include the FIV subtype A molecular clones 34TF10 and PPR, which were derived 
from cats that displayed significant disease symptomology. 34TF10 was able to infect 
CRFK (Crandell Rees Feline Kidney Fibroblast) and G355-5 (feline astrocyte cell line), 
whereas PPR was able to infect feline peripheral blood leukocytes50. 
Clone FIVC-36, a subtype C strain, was isolated from a cat that developed severe 
immunodeficiency disease, following which it was cloned. This molecular clone was able 
to infect feline peripheral blood mononuclear cells and primary T-cell lines. This clone 
was infectious and replication-competent in vitro and highly pathogenic in vivo. Sequence 
analysis revealed that this clone had a large amount of envelope sequence divergence 
from the two subgroup A strains – 76% from 34TF10 and 78% from PPR51. The highly 
pathogenic nature of FIVC-36 led us to utilize it in this project for our purposes.  
1.3.1 Comparison of FIV and HIV: Disease progression 
FIV infection in cats is very similar in pathogenesis to HIV in humans. Upon 
infection, cats undergo an acute phase of infection within the first few weeks where there 
is generalized lymphadenopathy, pyrexia, and anorexia. Circulating levels of FIV can be 
found within a few days of infection45. 
The acute phase is followed by an asymptomatic phase or latent phase that is 
characterized by negligible viral titer and minimal clinical symptoms. This asymptomatic 
phase can last from several months to several years, similarly to HIV infection46. Like 
HIV, CD4+ T cell loss is a hallmark of FIV infection, and this decline can start occurring 
as early as 4-6 weeks post infection45. Transition into the symptomatic phase and 
eventually feline AIDS occurs through the reduction of antiviral responses and increased 
secondary infections, such as gingivitis, pneumonia and rhinitis45. Neurotropic strains can 
also infect central nervous system microglia, astrocytes, and macrophages, clinically 
manifesting as aggressive behaviour, facial twitching, and delayed auditory and visual 
evoke responses45. Infected cats also experience increased susceptibility to opportunistic 
infections46. 
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1.3.2 Comparison of FIV and HIV: Structure and genome 
The FIV genome is approximately 9400 nucleotides long12, while HIV-1 is typically 
approximately 9200 nucleotides52. Both HIV and FIV share homology in their structural 
proteins but differ in their accessory proteins (Figure 3). 
 
 
 
 
Figure 3. Genome organization of FIV and HIV-1. Both are flanked by LTRs and contain 
gag, pol, and env. The accessory genes vif and rev are shared by both the viruses. The 
accessory genes of vpr, vpu, and nef are only found in HIV, whereas FIV encodes the 
accessory gene orfA. FIV pol precursor additionally contains DU (dUTPase). 
 
Like all retroviruses, the two viruses are flanked by long terminal repeats (LTRs), 
and contain the gag, pol, and env genes that code for structural proteins. The gag 
precursor encodes the p24 Capsid (CA), the p14 Matrix (MA), and p7 Nucleocapsid (NC) 
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in FIV and is cleaved by Protease. The corresponding counterparts in HIV are p24, p17, 
and p7, in addition to p6 that is implicated in the incorporation of Vpr into the virion53. 
The Gag proteins are necessary for assembly to form mature, infectious virion particles. 
The pol precursor is composed of Protease (PR), Reverse Transcriptase (RT), and 
Integrase (IN), with the addition of dUTPase (DU) in FIV12,43,45,46. 
Structurally, the virion’s capsid is surrounded by matrix proteins, whereas the 
nucleocapsid is tightly associated with the RNA genome. IN, PR, RT and dUTPase (FIV 
only) are packaged into the mature virion. PR is responsible for cleaving the Gag and Pol 
polyproteins. RT synthesizes cDNA from viral RNA. IN incorporates the cDNA into the 
host genome. dUTPase, a hallmark of FIV and equine infectious anemia virus (EIAV) is 
responsible for maintaining low levels of dUTP in the cell environment to prevent the 
mis-incorporation of uracil into DNA. This feature is not seen amongst primate 
lentiviruses43,46. Alternatively, HIV, but not FIV contains a trans-activator of transcription 
(Tat) that promotes RNA pol II transcription53. 
The Rev protein regulates nuclear export of mRNA for the two viruses, and exon 
1 of rev is located at 5’ of the env gene in both. However, exon 2 of rev is located at the 
far 3’ end of env in FIV, and within the transmembrane encoding region of env in HIV. 
Rev is implicated in the transport of unspliced or partially spliced, intron-containing RNA 
out of the nucleus using the CRM1 (exportin-1) pathway54. It does so by binding to the 
Rev Response Element (RRE) on the unspliced RNA12. 
The vif accessory gene is present in both HIV and FIV, and responsible for 
countering APOBEC3 enzymes that serves as host restriction factors. Specific human and 
cat APOBEC3 proteins are responsible for cytidine deamination of the viral genome 
resulting in deleterious G-to-A mutations. Vif antagonizes this function by directing 
APOBEC3 to the proteasome for degradation, preventing its incorporation into the 
virion46. The Vif of pathogenic versions of FIV has also been shown to increase the 
replication rate of the virus in vitro55. FIV lacks the accessory genes nef, vpu, and vpr 
seen in HIV. These are mainly responsible for increasing HIV virulence and disrupting 
the action of host restriction factors. Nef is a multi-functional protein known to interact 
with several host receptors. The most notable of its functions are CD4 downregulation by 
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targeting the receptor to the endo-lysosomal pathway, which promotes envelope 
incorporation and budding53,56. It also promotes MHC-1 downregulation on the cell 
surface56, deterring immune surveillance. Vpu also decreases CD4 expression but unlike 
Nef that targets CD4 present on the surface, Vpu targets newly synthesized CD4 in the 
endoplasmic reticulum. Additionally, Vpu also antagonizes BST2 (tetherin), a host 
restriction factor that tethers viral particles to the membrane, and is implicated in 
enhancing viral particle release34. Vpr also has several functions including the promotion 
of cell cycle arrest in the G2 phase where the LTR promoter is most active, facilitation of 
the nuclear import of the pre- integration complex in non-dividing cells, and control of 
apoptosis57. 
The accessory protein OrfA is unique to FIV. It has been implicated in 
downregulation of CD134 expression, as it is the primary entry receptor for FIV58, 
reminiscent of the downregulation of CD4 in HIV infection. It has also been implicated in 
altering the gene expression patterns of factors involved in post-transcriptional 
modifications, splicing machinery, and proteasome ubiquitination59. Although 
mechanistically different from HIV Tat, OrfA also regulates transactivation of mRNA 
synthesis60. Like HIV Vpr, FIV OrfA is implicated in inducing G2 cell cycle arrest61. The 
LTR is most active in the G2 phase. Lastly, OrfA has been implicated in viral infectivity 
as OrfA mutations can decrease infection of feline PBMCs62. These functions make OrfA 
an interesting, multifaceted accessory protein. 
1.3.3 Comparison of FIV and HIV: Entry receptor usage and cellular tropism 
FIV and HIV differ in their receptor usage. HIV utilizes CD4 as its primary 
receptor and either CCR5 or CXCR4 as its secondary receptor. FIV, on the other hand, 
utilizes CD134 as its primary receptor and CXCR4 as its co-receptor. As a consequence 
of this dependence on CD134 and CXCR4, FIV is not only tropic for T cells and 
macrophages, but also for B cells and CD8+ T cells12. Differences in HIV and FIV 
envelope are responsible for their differential cell tropism. 
Furthermore, HIV envelope is a major target for therapeutic strategies aimed at 
the infection. The RV144 trial that demonstrated the most promise for an anti-HIV 
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vaccine targeted the HIV envelope. It consisted of immunization of the ALVAC 
(canarypox vector), with the VAX B/E gp120 protein vaccine booster to elicit an anti-
gp120 antibody response. Glycan binding sites are of major importance as specific sites 
such as N-linked glycosylation epitopes are required for the binding of broadly 
neutralizing monoclonal antibodies63. Vaccine efficacy of the trial is linked to responses 
including the binding of IgG antibodies to variables loops 1 and 2, antibody-dependent 
cell cytotoxity, CD4+ T cell responses, and Env-specific IgA responses, all of which 
target components of the envelope7.  
Evidence as such has encouraged us to prioritize the importance of the HIV 
envelope in the process of establishing a novel animal model to study HIV.  
1.3.4 Comparison of FIV and HIV: Immune control of FIV infection 
FIV immune responses mimic HIV responses to some extent. For instance, in both 
infections, the CD4:CD8 ratio decreases as the number of activated CD8+ cells increases. 
Additionally, T regulatory cells that are CD25+/CD4+ are responsible for downregulating 
CD8+ T cells that produce IFN-γ. This is a potential immunosuppressive effect on CD8+ 
cells seen in both HIV and FIV12. 
Furthermore, FIV-infected cats are less responsive to mitogens-induced 
lymphocyte blastogenesis with both T and B cell mitogens. Culturing of keyhole limpet 
hemocyanin with PBMCs resulted in a lower primary proliferative response in FIV- 
infected cats, compared to non-infected animals, which is indicative of a lack of a robust 
naive T cell response to antigens64. This was proposed as a mechanism for opportunistic 
infections to be able to manifest. Dysfunction of T cell proliferation is also seen with 
HIV65. 
Grant et al. (2009) have also demonstrated that in addition to anti-SU antibodies, 
anti-CD134 autoantibodies were also produced in FIV-positive cats and their binding to 
CD134 induced the release of viral SU (surface component of Env) from the primary 
receptor, thereby blocking viral infection. This correlated with lower viral loads66. 
Similarly, anti-CCR5 autoreactive antibodies in HIV infection are implicated in 
downregulating CCR5 expression as an antiviral strategy67. 
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However, unlike HIV, a commercial vaccine for FIV called Fel-O-Vax-FIV® is 
available. It is a dual-subtype inactivated whole cell lysate virus composed of subtypes A 
(FIVPet) and D (FIVShi) FIV
68. Although effective against some FIV subtypes, including 
subtypes D and F69, prior work has shown that the vaccine is variable in its efficacy 
against varying subtypes and strains, which also includes differences within homologous 
subtype challenge responses, depending on the neutralization tier that the challenge strain 
belongs to70. The tier system categorizes virus subtypes according to their sensitivity to 
neutralizing antibody responses. Tier-1 FIV are homologous to the vaccine strains and 
most-sensitive to neutralizing antibody responses. Tier-2 comprise FIV that have 
homologous subtypes to the vaccine strains, but are more resistant to neutralizing 
antibody responses. Tier-3 FIV are least sensitive to neutralizing antibody responses and 
are composed of subtypes that are different, i.e., heterologous to the vaccine strains70. 
Protection against tier-1 FIVPet is strong; however, protection upon challenge with certain 
tier-2 and tier-3 subtype viruses is afforded to a lesser extent70. Passive antibody transfer 
studies have demonstrated that neutralizing antibody responses are not necessarily 
effective against heterologous subtype challenge, however, vaccine-induced T cell 
responses have been implicated in conferring protection in both homologous and 
heterologous challenges68. These most likely include T-helper 1 activity mediated by IL-2 
and IFNγ, and cytotoxic lymphocyte activity driven by the production of perforin69. 
Furthermore, a case-controlled field study in Australia revealed a protective rate 
of 56% in vaccinated cats69, as opposed to the maximum protection rate of 31.2% for 
HIV-1, as seen in the RV144 trial63. In addition to antibody mediated cell cytotoxicity 
(ADCC), protection in the RV144 trial was also attributed to anti-V2(Env) CD4+ T cell 
immunity including CD4+ cytotoxic T lymphocytes and polyfuctional CD4+ T cells68. 
The vaccine protection linked to T cell responses in HIV vaccines is similar to what is 
observed with FIV vaccines. Based on this, lessons from FIV vaccine trials can 
supplement knowledge that can be used to improve HIV vaccine efficacy. 
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1.4 Project rationale 
As outlined earlier, although mouse models and non-human primate models are 
effective and beneficial in studying HIV, there are several ethical, financial, and logistical 
issues that accompany utilizing these organisms. Cats, on the other hand, provide an 
avenue for a lower-cost model, as they are naturally infected by FIV. When considering 
genome structure, FIV and HIV share several similarities. Disease pathogenesis of FIV in 
domestic cats is also similar to HIV pathogenesis and AIDS progression in humans. 
Based on these similarities, cats serve as good candidates for being used as model 
organisms in studies aimed at developing HIV vaccines and therapeutics. 
A limitation of the FIV model is that its cellular tropism and receptor usage differs 
from HIV. Due to this, HIV therapeutics targeted towards the envelope cannot be 
effectively tested in cats infected with FIV. An improved model would include a version 
of FIV that utilizes CD4 and CCR5 for entry into cat cells and thus has similar tropism to 
HIV. 
When we compare their amino acid sequence, feline and human CD4 share 59% 
identity and 71% similarity (Figure 4a). When comparing CCR5 amino acid sequences, 
they share 76% identity and 86% similarity (Figure 4b). Percent identity here indicates 
the percentage of identical amino acids, while percent similarity accounts for the amino 
acids that are different, but share similar properties or characteristics. 
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a) CD4 alignment 
 
b) CCR5 alignment 
Figure 4. Alignment of cat and human amino acid sequences. a) CD4 alignment. Cat and 
human sequences share 59% identity and 71% similarity. b) CCR5 alignment. Cat and 
human sequences share 76% identity and 86% similarity. “*” denotes conserved residues. 
“:” denotes residues with strongly similar properties. “.” denotes symbols with weakly 
similar properties. 
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Based on this level of similarity, we hypothesize that HIV envelope could 
potentially utilize the feline counterparts of CD4 and CCR5 to enter cat cells. 
Furthermore, chimeric viruses composed of both HIV and FIV components wherein the 
envelope gene in the FIV genome is replaced by the HIV envelope gene (called FHIVenv 
from hereon) should be able to enter and infect cat cells. If these chimeras can replicate in 
vivo, HIV therapeutics and vaccines targeting envelope can be tested using cats. 
Although HIV can use either CXCR4 or CCR5 as its co-receptor, we are choosing 
to focus on CCR5-utilizing strains. Prior work has demonstrated that CCR5-utilizing 
strains are more likely to establish acute infections, regardless of the route of 
transmission71. These CCR5-utilizing viruses are more likely to dominate and become the 
founder population when present alongside CXCR4-utilizing variants during infection 
transmission71. In addition to this, individuals that carry the Δ32 mutation in CCR5 are 
still susceptible to CXCR4-utilizing variants; yet this occurs with a low frequency, 
suggesting that CCR5-utilizing variants are more likely to be transmitted72. Therefore, 
prophylactic HIV vaccines must be designed to prevent transmission of CCR5-utilizing 
strains and model systems for testing vaccines should focus on CCR5 tropic viruses. 
Thus, we aimed to make FHIVenv chimeras utilizing env from CCR5-utilizing variants. 
We sought to create these FHIVenv chimeras to express HIV envelope. FHIVenvs 
capable of adapting to utilize feline CD4 and CCR5 receptors to enter and infect cat cells 
in vitro will be tested in in vivo in cats in the future. Our long-term vision is to develop 
and isolate the FHIVenvs capable of replicating in vivo, which will allow for the use of 
cats as animal organisms to test HIV vaccines and therapeutics targeting envelope. An 
advantage of this model is that all the accessory genes (excluding FIV envelope) are 
retained in the FHIVenvs, which can allow the chimeric viruses to circumvent feline host-
restriction factors. Using intact HIV to infect cats would not guarantee the evasion of 
feline restriction factors, which could potentially target HIV at different points in its life 
cycle.  
This particular thesis’ aim was to lay the groundwork for this long-term project by 
testing its validity in vitro in cat cells. Throughout this project, we worked with the highly 
pathogenic FIVC-36 clone. We attempted to utilize the yeast recombination strategy73 to 
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make the plasmids required to produce FHIVenv chimeras, where HIV env would replace 
FIV env in the FIVC-36 backbone. For this, we started by testing whether infectious FIV 
could be produced from plasmid transfections of the vectors created using this cloning 
strategy. We tried several variations of the infection experiments with virus produced 
from these plasmids. We found little to no infectious FIV production. We also attempted 
alternate cloning strategies such as In-fusion cloning to make FHIVenvs but were not able 
to successfully generate them. The process of making the chimeras is currently ongoing 
in the Troyer/Arts Lab. 
We additionally engineered CRFK cat cell lines expressing feline or human 
CD4/CCR5 (referred to as feCD4/feCCR5 or huCD4/huCCR5 CRFK hereafter), which 
were necessary for the in vitro part of this study. We utilized them in cell-to-cell fusion 
assays testing receptor-envelope interactions between diverse HIV envelope expressed on 
293T cells and human or feline CD4 and CCR5 expressed on CRFK cells. Additionally, 
we utilized the cells expressing human CD4 and CCR5 in an infectivity assay with HIV.  
In the future, these cell lines can be used in cell-to-cell fusion assays to test 
diverse HIV envelopes (from CCR5-utilizing strains) and isolate the subtypes and strains 
that are capable of interacting with feCD4 and feCCR5 expressed on cat cells. These 
particular HIV envs can then be pursued further in the FHIVenv cloning process. 
Following this, FHIVenvs can be utilized in infectivity assays using feCD4/feCCR5 
CRDK to test their ability to replicate in vitro. The engineered huCD4/huCCR5 CRFK 
cell line can be used as the positive control for the cell-to-cell fusion and infectivity 
assays, as we expect HIV envelope to be able to bind these receptors to enter cells. Once 
replication-competent FHIVenvs are isolated from in vitro experiments, their ability to 
infect and replicate in vivo in cats can be tested. The steps required to accomplish the 
vision of this project are described in the flowchart in Figure 5. 
Overall, this study provides an avenue for testing therapeutics or vaccines that 
target the HIV envelope, using a suitable and cost-effective animal model. 
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Figure 5. Flowchart detailing the project plan. Engineered huCD4/huCCR5 CRFK and 
feCD4/feCCR5 CRFK can be used in cell-to-cell fusion assays to isolate HIV envelopes 
(expressed on 293T from cloned vectors) from diverse subtypes and strains that can interact with 
these human and feline receptors. These envs can be cloned into the FIV backbone to make 
FHIVenvs. The engineered cell lines can also be used in infectivity assays to test the capability of 
the FHIVenvs to replicate in vitro in cat cells. These FHIVenvs can then be pursued further to 
infect cat in vivo. The CRFK expressing huCD4/huCCR5 functions as the positive control for the 
fusion and infectivity assays as HIV envelope is tropic for these receptors.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Yeast recombination and miniprep 
The yeast recombination system was initially chosen to create the FHIVenv 
chimeras.  Prior to this, the vectors produced from this cloning system had to be tested for 
their ability to produce infectious FIV after being utilized for transfections.  
The yeast recombination system takes advantage of the yeast gap repair system 
where any double stranded DNA breaks can be repaired through the exchange of genetic 
material between damaged DNA and the intact DNA, if they share homology. The FIV 
genome of the virulent C3651 strain was cloned into the pREC_URA3 plasmid in place of 
URA3. This plasmid contains all the elements to promote replication in yeast including 
the yeast centromere (Cen6), autonomously replicating sequence (ARSH4), β-
isopropylmalate dehydrogenase (LEU2) that maintains plasmid growth in LEU2 deficient 
yeast on Leucine drop-out plates73. This plasmid also contains the orotidine-5′- phosphate 
decarboxylase (ODCase) gene called URA3. In the presence of 5-fluoroorotic acid (5-
FOA), URA3 would promote the reaction whereby a toxic by-product, 5-fluorouracil, is 
produced. Therefore, any yeast still carrying a URA3 containing plasmid post-
transformation would be selected against on C-Leu+5-FOA plates. 
The FIV genome had to be inserted into the pREC plasmid as two separate 
fragments. This is because the 5’ and 3’ LTRs are homologous and the co-existence of the 
two could result in either of them being recombined out during the homologous 
recombination process. Thus complement (cplt) extending from the 5’ LTR to gag 
(Figure 6), and the near-full-length (nfl) extending from gag to the 3’LTR (Figure 8) were 
PCR amplified separately and inserted into the pREC backbone independently. The 
complement supplied the 5’ LTR, whereas the nfl supplied the remainder of the genome. 
The nfl also contains the env sequence; it was synthesized with the intention of being 
used further to clone diverse HIV env in place of FIV env. An alternate version of the 
complement (cplt-rre) was also constructed to include the FIV Rev response element 
(RRE), an RNA secondary structure that promotes unspliced viral mRNA export through 
interaction with the FIV Rev protein (Figure 7). The nfl vector was transfected along with 
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the cplt or cplt-rre vector to produce FIV that was used for infections. 
The FIV genome was PCR amplified using primers that contained 40-80bp 
overhangs that shared homology with regions in the pREC plasmid flanking URA3 
(Table 2, primers 1 to 5 for nfl, primer 6 and 7 for cplt, primers 8 to 11 for cplt-rre). The 
pREC_URA3 was digested overnight to linearize the plasmid using the restriction 
enzyme SbfI, for which a cut site is present in URA3. Saccharomyces cerevisiae was 
cultured overnight in liquid YPD media. The yeast was pelleted by centrifugation at 
4000xg for 5 minutes, washed, and re-suspended in TE/LiAc solution. 3 µg linearized 
pREC_URA3, 1 µg PCR product insert, and 5 µl salmon sperm carrier DNA were added 
to 50 µl yeast. Each reaction tube was mixed with 300µl PEG and incubated in a 30°C 
shaker for 1 hour. Following this, the yeast was shocked in a 42°C water bath for 15 
minutes. Each reaction tube was centrifuged, after which the supernatant was discarded, 
and the yeast was resuspended in 100 µl sterile water and plated on C-Leu+5-FOA plates. 
The plates were incubated at 30°C for 2-5 days. 
For plasmid preparation, single yeast colonies were taken from each plate and 
cultured overnight in C-Leu+5-FOA liquid media. The culture was pelleted by 
centrifugation and treated with 200 µl breaking buffer (10ml breaking buffer – 2ml 10% 
Triton X-100, 1ml 10% SDS, 200µl 5M NaCl, 100µl 1M Tris-Cl pH=8.0, 20µl 0.5M 
EDTA, 6.68ml sigma water) to lyse the cells, followed by the addition of 0.3 g acid-
washed glass beads and 200 µL phenol/chloroform/isoamyl alcohol. This was vortexed 
and centrifuged, after which the aqueous phase was extracted. The DNA was ethanol 
precipitated and re-suspended in 20 µl sterile water. 10 µl of this was transformed into 
ElectroMAX Stbl4 bacterial cells. Single colonies were picked and screened via PCR and 
sequenced. 
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Figure 6. Yeast cloning strategy for creating the complementing plasmid that supplies the 
5’LTR. For the original cplt vector shown here, PCR amplification of the FIV template 
was conducted to generate a fragment that included the entire 5’ LTR and gag with 
primers containing 40bp overhangs that shared homology (blue and green boxes) with the 
pREC region flanking URA3 in pREC_URA3. pREC_URA3 cut with SbfI (which has a 
single cut site within URA3) was introduced with the PCR product into yeast, which 
facilitated recombination at sites that shared homology. The end product of this was 
pREC-cplt-FIV, where URA3 was replaced by the cplt fragment in the pREC_URA3 
backbone. 
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Figure 7. Yeast cloning strategy for creating the complementing plasmid that supplies the 
5’LTR, altered to include the RRE. For the cplt-rre vector seen here, the position of the 
forward primer for PCR was changed such that the it started at the R region of the 5’ LTR 
of FIV and contained a 65bp overhang that was homologous to the pREC sequence (blue 
box). Additionally, the RRE was amplified from the backbone as a separate PCR product. 
The forward primer of this contained a 65bp overlap with the first half of the cplt-rre PCR 
fragment (pink box). The reverse primer contained a 60bp overhang that shared 
homology with pREC (green box). Introduction of the two PCR fragments with SbfI-cut 
pREC_URA3 resulted in recombination at three sites – two sites were at the ends where 
recombination with the pREC regions flanking URA3 occurred and the third site was 
where recombination between the two PCR fragments occurred. The end product of this 
was pREC-cplt-rre-FIV, where URA3 was replaced by the cplt-rre fragment in the 
pREC_URA3 backbone. 
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Figure 8. Yeast cloning strategy for the near-full-length (nfl) plasmid. The plasmid was 
cloned to include the FIV genome, excluding the 5’ LTR. The nfl was introduced as two 
PCR fragments – the first fragment included the FIV sequences extending from the 
primer binding site to the middle of pol, while the second fragment had sequences 
extending from the middle of pol to the end of the 3’ LTR. The first fragment’s forward 
primer and the second fragment’s reverse primer contained 65-80bp overhangs that were 
homologous to the pREC sequences flanking URA3 in pREC_URA3 (green and blue 
boxes). Introduction of the two PCR fragments with SbfI-cut pREC_URA3 resulted in 
recombination at three sites – two sites at the ends where recombination with the pREC 
region flanking URA3 occurred, the third site where recombination between the two PCR 
fragments occurred (pink box). The end product of this was pREC-nfl-FIV, where URA3 
was replaced by the nfl fragment in the pREC_URA3 backbone. 
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2.2 Cloning of CD4 and CCR5 plasmids 
pBABE.huCCR5: The pBABE.CCR5 plasmid expressing human CCR5 as well as a gene 
for puromycin resistance was obtained from the NIH AIDS Reagent Program (Cat# 
3331). The pBABE vector contains a retroviral promoter from which the transgene of 
choice is expressed. It is typically used along with an envelope-expressing plasmid to 
generate retroviral vectors. For our purposes, the plasmid was directly used for 
transfections to generate stable cells lines expressing CCR5 (discussed in Section 2.4 of 
the Methods). 
pBABE.feCCR5: The huCCR5 gene was removed from the pBABE plasmid using New 
England BioLabs (NEB) restriction enzymes BamHI and SalI-HF, followed by gel 
extraction of the backbone with the QIAquick gel extraction kit. The feline CCR5 gene 
was amplified using the High Fidelity (HiFi) Platinum Taq (Thermo Fisher) protocol with 
primers containing overhangs overlapping with the restriction enzyme sites (BamHI and 
SalI) (Table 2, primers 22 and 23). Since the CCR5 gene is composed of a single exon 
with no introns, the coding sequence was amplified using laboratory cat blood DNA 
samples obtained from Colorado State University (CSU) as the template. PCR products 
were purified using the Agencourt AMPure XP PCR purification protocol. Products were 
ligated into the pBABE backbone using NEB’s T4 DNA ligase protocol. After identifying 
successful recombinants by restriction analysis, clones were sequenced. 
pBABE.huCD4: The pBABE.hygromycin empty vector was cut with NEB restriction 
enzymes SalI-HF and EcoRI-HF. huCD4 was PCR amplified from the T4-pMV7 plasmid 
obtained from the NIH AIDS Reagent Program (Cat# 158) using the HiFi Platinum Taq 
protocol with primers containing overhangs overlapping with the restriction enzyme sites 
(SalI and EcoRI) (Table 2, primers 24 and 25). The huCD4 product was ligated into the 
pBABE.hygromycin plasmid using NEB’s T4 DNA ligase protocol. After identifying 
successful recombinants by restriction analysis, the clones were sequenced. 
pBABE.feCD4: To amplify the feCD4 insert, Peripheral Lymph Node and Thymus RNA 
was obtained from a colony of lab cats at CSU. cDNA synthesis was conducted using the 
AccuScript Hi-Fi Reverse Transcriptase Kit, followed by nested PCRs using either the 
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HiFi Platinum Taq or Pfu Turbo DNA polymerase protocol (Table 2, primers 26 to 29). 
The same cloning strategy as huCD4 was used to insert feCD4 into the 
pBABE.hygromycin plasmid. 
A total of seven feCD4 and seven feCCR5 PCR products, each from a different 
laboratory cat, as well as ligated plasmids containing the respective genes were sequenced 
at the Eurofins Genomics facility in Toronto ON and compared to cat sequences in 
GenBank. The samples with the highest identities to the consensus amino acid sequences 
for feCD4 and feCCR5 were used for stable cell transfections. 
2.3 Cell culture of various cell lines 
Three cells lines were maintained in media composed of Dulbecco’s Modified 
Eagle Medium (DMEM), 10% Fetal Bovine Serum (FBS), and 1X Penicillin- 
Streptomycin (referred to as DMEM complete hereafter): 1) 293T cells - human 
embryonic kidney cell line (ATCC CRL-11268), 2) CRFK cells (Crandell Rees Feline 
Kidney) - feline fibroblast cells line (ATCC CCL-94), 3) GFox cells – CRFK cells 
expressing feline CD134 and green fluorescent protein (kindly provided by John Elder, 
UCSD). 
Cell lines generated via stable cell transfections were maintained in complete 
media along with drugs that maintained selection: 1) huCCR5 CRFK – DMEM complete 
with 5 µg/ml puromycin, 2) huCD4 CRFK – DMEM complete with 250 µg/ml 
hygromycin, 3) huCD4/huCCR5 CRFK – DMEM complete with 5 µg/ml puromycin and 
250 µg/ml hygromycin, 4) feCCR5 CRFK – 5 µg/ml puromycin, 5) feCD4 CRFK – 250 
µg/ml hygromycin, 6) feCD4/feCCR5 CRFK – 5 µg/ml puromycin and 250 µg/ml 
hygromycin. 
U87.CD4.CCR5 (NIH AIDS Reagent Program Cat# 4035), a human gliobastoma 
cell line, was maintained in DMEM complete containing 1 µg/ml puromycin and 300 
µg/ml geneticin. 
 
The cells were passaged every 2-5 days. Since all of these were adherent cell lines, they 
were washed twice with phosphate-buffered saline (PBS), followed with trypsin/EDTA 
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treatment and incubation for 5 minutes. The cells were then resuspended in DMEM 
complete (plus drugs for cells maintained under selection conditions) and split either 1:10 
or 1:20. 
All the cell lines were incubated at 37°C at 5% CO2. 
2.4 Generation of CD4 and CCR5-receptor expressing stable cell lines 
All transfections were conducted in 10 cm dishes with 3 million CRFK cells plated per 
dish and incubated overnight in DMEM complete. The media volume was adjusted to 7 
ml DMEM/10% FBS the next day. 1 ml of the transfection reagent was prepared by 
mixing DMEM with 72 µl FuGENE6 and 24 µg of the plasmid encoding the receptor, 
which was added to the plated cells. 24 hours post-transfection, the media was changed to 
15 ml DMEM complete (or any additional drugs for cells that were previously stably 
transfected and expressing a receptor). 48 hours post-transfection, the cells in the plate 
were harvested and split at ratios ranging from 1:2 to 1:20. At this point, the drug for 
which the transfected plasmid conferred resistance was added to the media. These were 
monitored for several days to weeks. Single colonies were then manually picked and 
passaged into individual wells of 96-well plates. The colonies that grew out in their 
respective wells were passaged further into larger flasks to be screened for receptor level 
expression. Table 1 lists the plasmids and cell types used for these transfections. 
 
Table 1. Plasmids to stably transfect CRFK cells to express CD4 and CCR5 and the drug 
resistance they confer. 
 
Cell line 
produced 
Transfected  
cells 
Transfection  
plasmid 
Drugs for which 
resistance is conferred 
huCCR5 CRFK CRFK pBABE.huCCR5 Puromycin 
huCD4 CRFK CRFK Cloned pBABE.huCD4 Hygromycin 
huCD4/huCCR5 
CRFK 
huCCR5 CRFK Cloned pBABE.huCD4 Puromycin/ 
Hygromycin 
feCCR5 CRFK CRFK Cloned pBABE.feCCR5 Puromycin 
feCD4 CRFK CRFK Cloned pBABE.feCD4 Hygromycin 
feCD4/feCCR5 
CRFK 
feCCR5 CRFK Cloned pBABE.feCD4 Puromycin/ 
Hygromycin 
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2.5 Flow cytometry and Fluorescence Activated Cell Sorting (FACS) 
The stable cell lines were tested by flow cytometry for receptor expression. Each 
cell layer was harvested using a cell scraper in order to leave surface receptors intact. The 
cells were stained with live-dead stain utilizing either BioLegend Zombie Violet (Cat# 
423113) or Zombie Aqua (Cat# 423101). In some instances, Invitrogen normal mouse 
serum (Cat# 31881) was used to block interactions between the antibodies being used and 
non-specific targets. 
The anti-human CCR5-PE antibody from either BioLegend (Cat# 359105) or BD 
Pharmingen (Cat# 550632) was used to detect huCCR5 expression. The anti-human CD4- 
BV711 antibody from BD Horizon (Cat# 563913) was used to detect huCD4 expression. 
feCCR5 was detected using a human/mouse/rat cross-reactive Novus Biologicals CCR5- 
PE antibody (Cat# FAB1802P). The CCR5 antibody is cross-reactive for human, mouse, 
and rat CCR5. feCD4 was detected using the feCD4-FITC antibody from Invitrogen 
(Cat# MA5-28776) or feCD4-FITC antibody from Bio-rad (Cat# MCA1346F). Staining 
and washes were conducted using flow cytometry buffer (PBS, 2% FBS, 0.5% Na-azide). 
After washing off the antibodies, the cells were fixed using the BD Cytofix/Cytoperm kit 
for fixation and permeabilization (Cat# 554714). 
Flow cytometry was conducted using either the LSR II or FACSCanto machine at 
the Robarts Flow Cytometry Facility. Flow sorting was conducted using the 
FACSAriaIII. Data analysis was done using FlowJo v10 6.1. 
2.6 RNA extraction 
CRFK cells that were transfected with the feCD4 plasmid were lysed using Trizol 
(Thermo Fisher) and RNA was extracted using the Trizol manufacturer’s protocol. The 
extracted RNA was treated with the Thermo TURBO DNA-free kit (Cat# AM1907) to 
eliminate any remaining DNA. This was followed by “RNA clean-up" purification using 
the QIAGEN RNeasy Mini Kit (Cat# 74104). 
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2.7 Transfections for virus production 
Transfections were conducted in either 6-well plates or 12-well plates to make 
virus. When 6- well plates were used, 800,000 293T cells or CRFK cells were plated in 3 
ml media and incubated overnight. One day later, the media volume was adjusted to 1 ml 
DMEM/10% FBS. 6 µg total plasmid was used for transfections. A double-stranded copy 
number calculator was used (https://cels.uri.edu/gsc/cndna.html) to calculate the amount 
of near-full-length (nfl) and complement (cplt or cplt-rre) plasmids (in ng) to add 
equivalent copies of the two plasmids. To make 1 ml of the transfection mix, DMEM was 
mixed with 18 µl FuGENE6 transfection reagent and incubated for 5 minutes. 6 µg total 
plasmid was added to this and incubated for 15 minutes. The transfection mix was added 
to the plated cells and incubated for 8 hours, following which the mix was replaced with 3 
ml DMEM complete. 48 hours post- transfection, the virus-containing supernatant was 
collected and centrifuged at 1500xg for 10 minutes to remove cells and cellular debris. 
The virus-containing supernatant was aliquoted into 1 ml portions and placed at -80°C for 
long-term storage. 
For smaller-scale transfection conducted in 12-well plates, 325,000 cells were 
plated overnight in 2 ml media. 1 day later, the media was replaced with 900 µl 
DMEM/10% FBS and 100 µl transfection mix (3 µg total DNA, 9 µl FuGENE6). Ratios 
ranging from 10:1 to 1:10 (calculated as ratio of µgs transfected) of nfl:cplt-rre were used 
for transfections, instead of equivalent copy numbers. 16 hours post-incubation, the 
media was replaced with 2 ml DMEM complete and collected 48 hours later. 
2.8 Virus infections 
Traditional: For FIV infections, 400,000 GFox cells (CRFK cells expressing 
CD134 – the primary receptor utilized by FIV for entry) were plated per well in a 6-well 
plate or 160,000 cells in a 12-well plate. 150-250 µl virus supernatant was mixed with 
DMEM complete and used to replace the plating media. 8-16 hours later, the media was 
replaced with fresh DMEM complete. Cultures were incubated for 7-10 days and 
monitored for syncytia formation, with 30 µl supernatant collected every 2-3 days for 
virus quantification by reverse transcriptase (RT) assay. AD8-HIV infection of 
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huCD4/huCCR5 CRFK (Colony M) was done using this method as well. 
Spinoculation: Spinoculations are infections where virus and cells are incubated 
together and centrifuged for several hours, followed by plating onto a dish. 100,000 GFox 
cells were aliquoted into 15 ml conical tubes. These were centrifuged at 300xg for 5 
minutes, following which the DMEM media was removed. The cells were resuspended in 
1 ml virus supernatant. These were “spinoculated” by centrifugation at 4000 rpm in the 
Sorvall Legend™ T / RT Centrifuge with a swinging bucket rotor (Model 7500 6434) 
containing round buckets (Order #: 7500 6441). This is approximately 3400xg. 
Spinoculations were conducted for 3 hours at 32°C. At the end of the spin, the 
supernatant was taken off and the cells were resuspended in DMEM complete and 
transferred into 6-well plates at a total volume of 3 ml per well. Cultures were monitored 
and maintained for up to a week, with 30 µl supernatant collected every 2-3 days for RT 
assay. 
2.9 Reverse Transcriptase (RT) assay 
10 µl of virus-containing supernatant was incubated with 20 µl RT buffer (5% 1M 
Tris, pH 7.5; 3.75% 2M KCl; 0.5% 1M MgCl2; 0.5% NP40; 50% Poly (rA)-p(dT) 
(1U/ml); 0.2% 1M DTT; 40.05% Sigma water) in a round-bottom 96-well plate for 20 
minutes for detergent-mediated viral lysis to occur. A master mix of 0.04 µCi/µl 
radiolabelled solution was created using 32P (10 µCi/µl) - radiolabeled TTP at the alpha 
phosphate position and RT buffer. 5 µl of this master mix was added to each well. The 
plate was incubated for 2 hours to overnight at 37°C. Following this, 10 µl of the contents 
of each well were spotted onto Whatman DE81 filter paper containing a 96-well grid. 
This was allowed to dry before washing to eliminate excess unincorporated 
32P. The mats 
were placed on a rocker and washed at least five times with 1X Saline Sodium Citrate 
(8.8 g/L Sodium Chloride, 4.4 g/L Sodium Citrate, pH 7.0) and two times with 85% 
ethanol for five minutes each. After the washes, the mats were dried by being placed on 
65°C heat block for 10-15 minutes. They were then deposited into a plastic cover and 
placed facing a blanked phosphorimager screen inside a cassette overnight. The screen 
was imaged using the Amersham Bioscience Storm 820 Phosphorimager. 
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2.10 In-fusion cloning 
As an alternative approach to clone the FHIVenv chimeras, the In-fusion cloning kit 
was used. This is because RT assay results revealed that the yeast cloning strategy did not 
produce infectious FIV particles (details discussed in the Results and Discussion 
sections). This cloning strategy can fuse DNA that share a 15bp overlap. For the FIV 
backbone, primers were designed to amplify around the FIV-C36 plasmid to include all 
components excluding the envelope (Table 2, primers 12 to 16). These primers were also 
positioned to include or exclude distinct portions of the FIV env sequences, in order to 
clone various diverse FHIVenv chimeras. To amplify the HIV envelope inserts, primers 
positioned on either sides of the envelope with 15bp overhangs (sharing homology with 
corresponding FIV sequences) were used for amplification (Table 2, primers 17 to 21). 
The PCR products were treated with the enzyme DpnI that cleaves methylated DNA and 
would theoretically cleave whole FIV plasmid. The PCR product of the HIV envelope 
was gel extracted using the Qiagen Gel Extraction kit. A reaction was set up including the 
insert, vector, and 5X In-fusion HD Enzyme Premix from Takara Bio (Cat# 102518) 
following the manufacturer’s protocol in the In-fusion HD Cloning Kit User Manual. The 
reaction mix was transformed into Stellar cells supplied as part of the In-fusion kit. 
Several methods were attempted to eliminate carry through of whole plasmid including 
DpnI digestion, PCR purification, and gel extraction of the PCR products. 
2.11 Cell-to-cell fusion assays 
The assay is used to test fusion between cells due to receptor-envelope 
interactions. pREC-nfl-HIV is comprised of the near-full-length HIV genome under the 
control of the CMV promoter. This vector allows for the expression of HIV proteins but 
does not produce infectious virus particles as it lacks the 5’ LTR. It was transfected into 
293T, resulting in HIV envelope expression on the cell surface. Upon being incubated 
with cells expressing CD4 and CCR5 receptors (the receptors traditionally utilized by 
HIV envelope to enter and infect human cells), the two cell types should theoretically 
fuse due to receptor-envelope interactions, which can then be quantified as described 
below74. This system was used to test receptor-envelope interactions between HIV 
33  
 
envelope and human CD4/CCR5 or feline CD4/CCR5. 
Two varying versions of the assay were used for this project – the luciferase 
system, and the β-galactosidase system. The former is dependent on luciferase expression 
from the pDM128fLuc plasmid, which is under the control of HIV Rev and Tat. The 
plasmid is transfected into the cells that express the receptors. If fusion occurs upon 
incubation of the receptor-expressing cells with the envelope-expressing cells, Rev and 
Tat produced in the pREC-nfl-HIV-transfected 293T should be able to drive the 
expression of luciferase in the CD4/CCR5 expressing cells75,76. The latter is a variation of 
the α-complementation system. The α and ω portions of the β-galactosidase protein are 
enzymatically inactive independently, but active when expressed together77. The α 
portion is transfected into the pREC-nfl-HIV-transfected 293T, and the ω portion into 
cells expressing the receptors. If fusion occurs, the products of the two fragments can 
interact to produce the reconstituted product of the β-galactosidase gene77. 
pREC-nfl-HIV samples included subtype A, B, C, and D samples that were cloned 
into the pREC backbone. Subtypes A, C, and D backbones were isolated from Uganda 
and Zimbabwe patient cohorts. Subtype B were isolated from America and Belgium 
patient cohorts. These had been cloned previously in the Eric Arts Lab. Table 4 contains a 
list of all the pREC-nfl-HIV plasmids used.  
Envelope expression: 700,000 cells/well 293T were plated in 6-well plates and 
incubated overnight. Independent transfections were conducted to express envelopes from 
varying pREC-nfl-HIV. The α portion of the β-galactosidase gene was additionally 
transfected into these when implementing the β-galactosidase system. No other vectors 
apart from the pREC-nfl-HIV plasmids were transfected when implementing the 
luciferase system. 
Receptor expression: The luciferase assay was first attempted with 293T cells that 
were triple-transfected with CD4 and CCR5 vectors to express the two receptors, along 
with the pDM128fLuc plasmid. In alternate versions of the assay, stable cell lines of 
CRFK and U87 already expressing CD4 and CCR5 were utilized and they were tested 
using the luciferase system as well as the β-galactosidase system. 600,000 cells/well 
U87.CD4.CCR5 and 500,000 cells/well huCD4/huCCR5 or feCD4/feCCR5 CRFK cells 
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were plated. These were transfected with the pDM128fLuc plasmid when the luciferase-
detection assay was used. When the β-galactosidase system was used, these cell lines 
were transfected with the ω fragment of the gene. 
For transfections, the cells were plated and allowed to incubate overnight. The 
media in each well was replaced with 1.8 ml DMEM/1% FBS the next day. To make the 
transfection mix for each well, 12 µl Polyethyleneimine (PEI) was mixed with Opti-
MEM media to total a volume of 150 µl and incubated for 5 minutes. A total of 4µg 
plasmid was mixed with Opti-MEM to total a volume of 150µl. The plasmid and 
transfection reagent media were mixed together and incubated for 20 mins. This was 
added to each well on the plate and incubated for 4 hours, after which the media was 
replaced with DMEM/10% FBS. 
48 hours post-transfection, the cells were lifted from the plate as follows. Each 
well was washed thrice with PBS. 6.24 mM EDTA (500µl) was added to each well and 
incubated at 37°C for 10 minutes. Post-incubation, 1ml DMEM complete was added to 
each well and pipetted to break any cell clumps, following which they were counted using 
a hemocytometer. Cells of each well were centrifuged at 200xg for 5 minutes and 
resuspended to a concentration of 2 million cells/ml, of which 50µl of the cells (100,000 
cells) expressing the receptors (and the pDM128fLuc plasmid for the luciferase system or 
the ω plasmid for the β-galactosidase system) were added to independent wells in a 
round-bottom 96-well plate. These were mixed with 50 µl of cells expressing a pREC-nfl- 
HIV plasmid (and the α plasmid for the β-galactosidase system). The cells were pelleted 
to the bottom of the plate by pulse centrifugation for 5-10 seconds and incubated for 18- 
24 hours at 37°C/5%CO2. If fusion occurs, treatment of the mixed cells with either the 
luciferase or the β-galactosidase substrate should produce a luminesce signal. The 
luminescence level is a measure of the receptor-envelope interactions.  
For measuring luminescence in the luciferase system, each well was treated with 
100 µl Britelite plus (Cat# 6066766), which contained a lysis buffer, as well as the 
substrate. The entire volume of each well was transferred into a black plate. Relative 
Light Units (RLU) were quantified using the Cytation 5 Imaging Reader. 
For measuring luminescence in the β-galactosidase system, the cells were spun at 
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530xg for 4 minutes. The media was removed and 100µl lysis buffer was added to each 
well and spun at 600rpm for 5 minutes on an Eppendorf MixMate plate shaker (Cat# 
2137900) to facilitate lysis. The plate was then incubated for 10 minutes at room 
temperature. It was centrifuged at 1200xg for 7 minutes. A volume of 10µl was 
transferred into a white plate and 100µl of the substrate, Galacto Star (appliedbiosystems 
Cat# T1012) diluted 1:50 in buffer, was added. This was incubated at room temperature 
in the dark for 50 minutes on a platform shaker, following with the reading was 
conducted. Relative Light Units (RLU) were quantified using the Cytation 5 Imaging 
Reader. 
2.12 Graphing and statistical analysis 
GraphPad Prism 8 was used to construct the graphs and conduct statistical analysis 
for all cell-to-cell fusion assay figures. A one-way ANOVA followed by Tukey’s post-
test was performed to compare the mean RLU for each full envelope to the mean RLU for 
SG∆env. This was performed for huCD4/huCCR5 CRFK as well as U87.CD4.CCR5. 
“*”, p<0.05; “**”, p<0.01; “***”, p<0.001. 
2.13 Alignments 
Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/) or BioEdit (for 
Windows 95/98/NT/XP) were used for sequence alignments. Percent Identity and Percent 
Similarity calculations were conducted using BLAST. 
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Table 2. List of primers used for PCR amplifications. 
 
 Primer Name Sequence Purpose 
1 
pREC-FIVC-F3 
 
TTGACGCAAATGGGCGGTAGGCG
TGTACGGTGGGAGGTCTATATAA
GCAGAGCTCTCTGGCTAACGTTG
GCGCCCGAACAGGGACT 
PCR 
amplification 
for yeast 
cloning – nfl 
2 FIVC-4715R GCATTATTGCTTTGACTGTGC 
3 FIVC-4650F CAGGATTCCTTTGGGCACA 
4 pREC-FIVC-R3 
GTTGGGATTCCATTTTTAATAAG
GCAATAATATTAGGTATGTAGAT
ATACTAGAAGTTCTCCTCGTGCG
AAGTCTTCGGC 
5 pREV-FIVC-R4 
GATTTTGATGTAATTGTTGGGATT
CCATTTTTAATAAGGCAATAATA
TTAGGTATGTAGATATACTAGAA
GTTCTCCTCGTGCGAAGTCTTCGG
C 
6 nfl-cplt-1F 
TACGGTGGGAGGTCTATATAAGC
AGAGCTCTCTGGCTAACTGGGAT
GAGTATTGGGACCCTGA 
PCR 
amplification 
for yeast 
cloning - cplt 7 nfl-cplt-2030-R2 
AATAATATTAGGTATGTAGATAT
ACTAGAAGTTCTCCTCGCAGGTC
TTCTGTCTAATGTTGTAGTGG 
8 RRE-fwd 
AGACATTGTTAGATTTATAAATT
ATAATAAAGTGGGTACCACTACA
ACATTAGACAGAAGACCTGGATG
AGGAATTGTCACAAAATATG 
PCR 
amplification 
for yeast 
cloning – cplt-
rre 
9 RRE-rvrs 
GATTCCATTTTTAATAAGGCAAT
AATATTAGGTATGTAGATATACT
AGAAGTTCTCCTCGCTTTTCCCTT
ATAATACAGAGTTTATTAA 
10 cplt-r5-f 
TTGACGCAAATGGGCGGTAGGCG
TGTACGGTGGGAGGTCTATATAA
GCAGAGCTCTCTGGCTAACGAGT
CTCTCAGTTGAGGACTTTCG 
11 cplt-2030R 
CAGGTCTTCTGTCTAATGTTGTAG
TGG 
12 env-ext-5prime 
TAACATTGTAACAAGTGTTATTT
GCACA 
PCR 
amplification 
of FIV 
backbone for 
In-fusion 
cloning 
13 env-ext-3prime TGGAATGGTAACCCAATATCA 
14 env-int-5prime GACTACTAAGGGTGGGAGTCT 
15 env-int-3prime-ct TGCTTACCTACATTGCTTGATT 
16 env-int-3prime-rre 
ATAGATGATGAGGAATTGTCACA
A 
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17 AD8-env-fivf 
CCACCCTTAGTAGTCATGAGAGT
GAAGGAGAAGTATC 
PCR 
amplification 
of HIV 
envelope for 
In-fusion 
cloning 
18 YU2-env-fivf 
CCACCCTTAGTAGTCATGAGAGC
GACGGAGAT 
19 hiv-env-fivct 
CAATGTAGGTAAGCACTGCCTAA
CTCTATTCACTATAGAA 
20 AD8-env-fivrre 
TTCCTCATCATCTATCTCAGCTAC
TGCTATGGCTGT 
21 YU2-env-fivrre 
TTCCTCATCATCTATCTCAGCTAC
TGCTATAGCTGTG 
22 feCCR5-F1 
CTTGGATCCCGTCGAGCAAAATG
GATTAT feCCR5 
amplification 
23 feCCR5-R1 
CTTGTCGACGTACAAACACCCGG
TCCA 
24 huCD4-F1 
TATTGAATTCGCCACCATGAACC
GGGGAGTCCCT huCD4 
amplification 
25 huCD4-R1 
TATTGTCGACTCATCAAATGGGG
CTACATGTCTTC 
26 feCD4-Fexternal CTGCCTCAGCAAGGCCACA 
feCD4 
amplification 
27 feCD4-Rexternal AAGCTCCCCGGTCCTGTGC 
28 feCD4-F2 ATGCCTTACAGGCTCCTC 
29 feCD4-R2 AGCGGGAGTGAGTCCATCAT 
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Table 3. List of plasmids used in this project 
 
Plasmid Purpose Source 
pBABE.huCCR5 Cell line generation transfection NIH 
pBABE.hygro 
Cloning of feCD4 and huCD4 
plasmids 
Yong Gao Lab 
pBABE.huCD4 (4) Cell line generation transfection Cloned 
pBABE.feCCR5 (4657-3) Cell line generation transfection Cloned 
pBABE.feCD4 (4370T) Cell line generation transfection Cloned 
FIVC-36 plasmid Virus production, yeast cloning Elder Lab (UCSD) 
pREC_URA3 Yeast cloning Gao Lab 
cplt Virus production Cloned 
cplt-rre Virus production Cloned 
nfl-3 Virus production Cloned 
nfl-6 Virus production Cloned 
pDM128fLuc VERITROP assay Arts Lab 
pREC-nfl-HIV plasmids VERITROP assay Arts Lab 
SG3∆env VERITROP assay Arts/Gao Lab 
pCMVα VERITROP assay Arts Lab 
pCMVω VERITROP assay Arts Lab 
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CHAPTER 3: RESULTS 
3.1 Yeast cloning system to produce FIV particles 
3.1.1 Weak RT activity is detected with FIV produced from the two-plasmid 
system using cplt and nfl 
The first step in producing recombinant FIV/HIV viruses was to generate yeast 
cloning vectors containing the complete FIV genome split into two parts – cplt and nfl 
(Figure 6 and 8) that can produce replication competent virus upon co-transfection of 
cells. The yeast cloning system was used to insert the FIV cplt and nfl fragments into the 
pREC backbone. The plasmids were verified by restriction digests and PCR screening 
post yeast-cloning, miniprep, and bacterial transformations. Additionally, each was 
thoroughly sequenced. Two nfl versions, nfl-3 and nfl-6, were chosen to proceed with, 
along with cplt-3. Sequencing showed that both nfl plasmids contained several sporadic 
points mutations distinct from the original FIV sequence (Figure 9). It is unknown 
whether these could impact the production of infectious virus particles, or effect 
replication competence and fitness. No such point mutations were seen in the cplt 
plasmid. 
 
 
Figure 9. Point mutations seen in the two clones nfl plasmids. The first sequence 
represents the expected pREC-nfl-FIV. The second sequence represents nfl-3 and the 
third sequence represents nfl-6. 
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The two plasmids of nfl and cplt were transfected into CRFK cells and 293T cells 
to produce virus particles. Transfection supernatants containing virus were used to infect 
GFox cells (CRFK cells expressing the FIV receptor CD134) to evaluate viral replication. 
Activity of the reverse transcriptase enzyme in cell supernatant was used to quantify virus 
particles. The RT assay (Figure 10) demonstrated that there was stronger virus production 
from transfection of 293T cells in comparison to CRFK cells. Additionally, attempts to 
concentrate the virus using Amicon filters did not appear to increase virus concentration.  
Furthermore, a strong positive signal indicative of virus replication was not 
observed post-infection for any virus produced using the two-plasmid system, and a faint 
signal is visible for the positive control. The virus for this positive control was made by 
transfecting the whole FIV-C36 plasmid into 293T cells. An additional positive control 
with FIV that was previously produced in the lab was used as the RT assay control. 
 
 
Figure 10. RT assay of FIV produced using the nfl and cplt plasmid cloned by the yeast 
complementation system. The assay was conducted on supernatants collected post- 
transfection (unconcentrated (lane 1) and concentrated (lane 2) supernatant), as well as 6 
days post- infection (lane 3). The strong positive signal seen in lane 4 (FIV (+) control) is 
from FIV that was produced previously in the lab after several passages, to serve as a 
control. 
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3.1.2 Addition of the FIV RRE to the cplt vector does not improve virus 
production 
According to previous data from the Eric Arts Lab, yeast cloning vectors using a 
different strain of FIV demonstrated that RNA was being transcribed from the cplt vector, 
however, it was not being exported to the cytoplasm (A. Moghadasi and E. Arts, 
unpublished data). Thus, it was hypothesized that the cplt RNA was hindered from being 
shuttled out of the nucleus as it did not contain the Rev Response element (RRE). FIV 
Rev protein binds the RRE and facilitate the transport of RNA out of the nucleus. 
Therefore, we concluded that cplt RNA was not reaching the cytoplasm to be packaged 
into new virus particles. In accordance with this, the cplt plasmid was altered to include 
the RRE (Figure 7). 
The cplt-rre plasmid also contained a couple of point mutations not seen before 
(Figure 11). 
 
Figure 11. Point mutations seen in cplt-rre. The first sequence represents the expected 
cplt-rre sequence. The second sequence is of cplt-rre-1A, the clone that was pursued for 
transfections and infections. 
 
Cplt-rre was transfected with either nfl-3 or nfl-6 into 293T cells. The virus was 
used to infect Gfox cells. The RT assay (Figure 12a) demonstrated that virus production 
post- infection did not increase, in contrast to the positive control. The virus harvested on 
day 9 post-infection was used to infect GFox cells for a second passage. This was 
monitored by RT assays (Figure 12b). Again, levels of RT activity did not demonstrate 
increases indicative of virus replication, in contrast to the FIV positive control. 
 
42  
 
 
a)                           a) Passage 1                                              b) Passage 2 
b)      
Figure 12. RT assay of Gfox infection with virus made using cplt-rre and nfl-3 or nfl-6. 
Virus-containing 293T transfection supernatant was used to infect GFox cells. a) Passage 
1 was continued for 9 days, after which the virus was added to newly plated Gfox cells. b) 
Passage 2 of Gfox cells was continued for 10 days post-infection. 
3.1.3 Altering the ratio of nfl to cplt during transfections produces FIV with 
weak RT activity 
Furthermore, to attempt to produce infectious virus, the approach to control the 
ratio of cplt-rre to nfl plasmid during transfections was undertaken, as this was previously 
an effective strategy for HIV production in the Eric Arts Lab. The ratio range extended 
from 10:1 to 1:10 of nfl:cplt plasmid. This was done independently for nfl-3 and nfl-6. 
Supernatants were collected two days after transfection and used to infect GFox cells 
(Figure 13). The infection was continued for two passages where the virus harvested on 
day 11 of passage 1 was applied to GFox cells for a second passage. No detectable virus 
production was observed with either nfl-3 or nfl-6 ratio-controlled infections, in contrast 
to the FIV positive control which demonstrated increased RT activity during the first 
passage and strong positive results later in the second passage. 
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a) Passage 1 
 
b) Passage 2 
 
 
Figure 13. RT assays of Gfox infection with viruses made through ratio-controlled 
transfections. Ratios are indicative of nfl:cplt-rre a) Passage 1. b) Passage 2. Passage 1 
ended on Day 11 and Passage 2 on Day 10. 
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3.1.4 Spinoculation of FIV on to GFox cells does not enhance infectivity  
Spinoculations on GFox cells were done using selected viruses produced through 
ratio-controlled transfections. Spinoculations are centrifugal infections wherein the virus 
and cells are mixed together and centrifuged for several hours. Enhanced HIV infectivity 
has been demonstrated using spinoculations and the mechanism for this has been 
proposed to be due to increased viral deposition on the cell surface78. Thus, we attempted 
to use this protocol to test whether enhanced FIV infectivity was possible using virus 
produced from the two-plasmid system. The spinoculations were continued for two 
passages and were only performed using nfl-6, as it seems to produce virus with slightly 
higher RT activity than nfl-3, as seen in Figure 12. The positive control showed 
increasing RT activity during the first passage and strong signal starting at day 4 of the 
second passage. Spinoculations using virus produced from the two-plasmid transfection 
utilizing nfl-6 and cplt-rre did not result in Gfox infection (Figure 14). 
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Figure 14. RT assay of spinoculations done with virus produced through ratio-controlled 
infections using cplt-rre and nfl-6. Supernatants of virus produced using 293T that were 
transfected with different ratios of nfl-6 and cplt-rre were used to spinoculate Gfox cells 
for Passage 1 that ended on day 6 post-infection. The supernatant of Passage 1 was 
applied on newly plated Gfox cells for a second passage that was continued for 7 days. 
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3.2 Sequencing lab cat feCD4 and feCCR5 to find the amino acid sequences 
with highest identity to the consensus sequence 
feCD4 and feCCR5 vectors were cloned for CRFK transfection to generate stable 
cell lines expressing either of the receptors, in addition to a cell line expressing both. 
Prior to cloning feCD4 or feCCR5 into the pBABE plasmid, DNA and RNA samples 
from lab cats were obtained and sequenced. This was conducted because of the lack of 
available sequences in GenBank, as well as the expectation that diversity exists in both 
CD4 and CCR5, depending on the cat colony from which the samples are retrieved. Only 
one sequence was available through GenBank (AAB24450.1) for feline CD4 and only ten 
complete feline CCR5 sequences were available, which made it imperative to sequence 
several more samples. 
For feline CCR5, twelve sequences, some of which were only partial, were 
available in GenBank, and seven more were sequenced from a lab cat colony. Sample 
4657 (also referred to as 4657-3 in the Troyer Lab) was most identical to the consensus 
sequence (Figure 15) and was cloned into the pBABE.puro plasmid. 
Sequencing seven cat samples from a lab cat colony at CSU revealed relatively 
low genetic diversity in feCD4, with only seven amino acid positions having 
polymorphisms. Sample feCD4 4370 (also referred to as 4370T in the Troyer Lab) was 
most identical to the consensus sequence (Figure 16), and it was cloned into the 
pBABE.hygro plasmid. Increased genetic diversity was seen for CCR5 between 
individual cats from the same colony, when compared to CD4. 
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Figure 15. Feline CCR5 alignment. The first twelve sequences were obtained from 
GenBank. The remaining seven were sequenced in this thesis. “*” denotes conserved 
residues. “:” denotes residues with strongly similar properties. “.” denotes symbols with 
weakly similar properties. 
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Figure 16. Feline CD4 alignment. The first input sequence was obtained from GenBank. 
The remaining seven were sequenced in this thesis. “*” denotes conserved residues. “:” 
denotes residues with strongly similar properties. “.” denotes symbols with weakly 
similar properties. 
3.3 Generation of cat cell lines expressing CD4 and CCR5 
3.3.1 Flow cytometry gating strategy to screen CD4 and CCR5 expression 
level 
Flow cytometry was performed over the course of this aim to screen the level of 
CD4 and CCR5 expression on the cell surface of transfected CRFK. For our purposes, the 
cell population was first gated using the forward scatter and side scatter to eliminate any 
debris. A live/dead stain was utilized so that the live cells could be gated from the total 
population for analysis. Positive CD4 and CCR5 cells were evaluated from the live cells 
(Figure 17). 
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Figure 17. Representative figure of the gating strategy used to evaluate CD4 and CCR5 
positivity on CRFK cells. SSC-A: Side Scatter (Area); FSC-A: Forward Scatter (Area). 
3.3.2 CRFK cells were successfully stably transfected to express huCD4, 
huCCR5, or both 
Cat cell lines expressing human CD4, human CCR5, or both were sought to be 
generated to conduct infection experiments and cell-to-cell fusion experiments. 
pBABE.huCCR5 and pBABE.huCD4 were transfected independently into CRFK cells 
and the cells were cultured with appropriate selective drugs: puromycin for CCR5 and 
hygromycin for CD4. Drug-resistant colonies were transferred to 96-well plates and 
grown under continued drug selection. Six and three colonies from the respective 96-well 
plates were expanded into larger cultures and tested for receptor expression by flow 
cytometry. Colony 9 had the highest level of huCCR5 expression with 27.2% of the live 
cells expressing the receptor (Figure 18a). Colony 10 had the highest level of huCD4 
expression, with 37.1% of the live cells expressing the receptor (Figure 18b). 
huCD4 CRFK (Colony 10) was used for pBABE.huCCR5 transfections to 
generate the huCD4 and huCCR5 double-positive cell lines. Nineteen colonies from the 
96-well plate were passaged and grown in selection media containing puromycin and 
hygromycin. These were screened by flow cytometry (Figure 18c). The percentage of 
cells that were double-positive ranged <1% to 43.4% of the live cells, across various 
colonies. Colony M had the highest percentage of cells that were positive for huCD4 and 
huCCR5. 
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a) huCCR5 CRFK 
 
b) huCD4 CRFK 
c) huCD4/huCCR5 CRFK 
 
 
 
Figure 18. Flow cytometry screen of human receptor-expressing cell lines. a) huCCR5 
CRFK. b) huCD4 CRFK. c) huCCR5/huCD4 CRFK. All cell lines screened are not 
included. 
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Colony M of huCD4/huCCR5 CRFK was pursued further for FACS to obtain a 
pure population. Figure 19 demonstrates the gating strategy used. Figure 19a and 19b 
represent the Fluorescence Minus One (FMO) controls. This control includes all the 
antibodies, except one. FMOs are used to ensure that fluorescence spillover from other 
fluorochromes into the given channel are not recorded as positives. They are useful in 
setting the gates to record true positives. Figure 19a and 19b are FMO controls for CD4 
(stained with PE-CCR5 and viability dye only) and CCR5 (stained with BV711-CD4 and 
viability dye only), respectively. Figure 19c represents the gate for CD4+/CCR5+ cells 
that were sorted out. Figure 19d represents an analysis of the purity of the cells post-
sorting, which showed that there was 99.5% huCD4/huCCR5 double positivity. Flow 
cytometry was conducted in the same colony to compare the populations pre and post-sort 
(Figure 20a and 20b). After the cells were grown up and passaged for 8 days, flow 
cytometry was conducted on them again to check the level of double positivity (Figure 
20b) and compared to the level of double positivity on the same cell colony before 
conducting FACS (Figure 20a). There was an overall shift in the entire population where 
a larger number of cells were double positive for CD4 and CCR5 and had higher MFIs 
(Mean Fluorescence Intensities). The MFI is indicative of the level of antibody 
expression. 
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a)       b)  
c)      d)  
Figure 19. Fluorescence activated cell sorting to obtain double positive huCD4/huCCR5 
cells. a), b), and c) represent the strategy to gate on the cells that are positive for huCD4 
as well as huCCR5. a) CD4 FMO b) CCR5 FMO c) Gate for CD4+/CCR5+ double 
positive cells that were sorted out d) Test of double positive cells post-sort. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
Figure 20. Flow cytometry conducted on huCD4/huCCR5 CRFK to compare the level of 
CD4 and CCR5 expression on Colony M before and after sorting a) Pre-sort b) Post-sort. 
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3.3.3 CRFK cells were successfully stably transfected to express feCD4, 
feCCR5, or both  
Cat cell lines expressing feline CD4, feline CCR5, or both were sought to be 
generated to conduct infection experiments and cell-to-cell fusion experiments. CRFK is 
a cat cell line that does not express either of these receptors. They were transfected with 
the pBABE.feCCR5 (4657) plasmid that had the highest identity with the consensus 
feCCR5 sequence. Eighteen colonies were grown up from a 96 well plate, passaged for 
several weeks in media containing puromycin, following which they were screened by 
flow cytometry. Colony 4 had the highest level of feCCR5 expression, with 95.6% of the 
live cells expressing the receptor (Figure 21a). 
The pBABE.feCD4 (4370) was transfected into CRFK cells as it had the most 
consensus cat CD4 sequence. Thirteen single colonies were picked, passaged, and grown. 
Colony 3 had the highest level of feCD4 expression, with 52.7% of the live cells 
expressing the receptor (Figure 21b). 
feCCR5 CRFK (Colony 4) was used for pBABE-feCD4 (4370) transfections to 
generate the double positive cell line, as it had the highest level of feCCR5 expression. 
Sixteen colonies were picked and passaged and screened by flow cytometry of feCD4 and 
feCCR5 expression. Colony 2O had the highest level of feCD4/feCCR5 expression with 
8.59% of the cells expressing both receptors (Figure 21c). 
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a) feCCR5 CRFK 
 
 
b) feCD4 CRFK 
 
 
c) feCD4/feCCR5 CRFK 
 
 
Figure 21. Flow cytometry screen of feline receptor expressing cells. a) feCCR5 CRFK b) 
feCCR5 CRFK c) feCD4/feCCR5 CRFK. The CCR5 antibody is cross-reactive for 
human, mouse, and rat CCR5. 
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3.4 huCD4/huCCR5 CRFK can support HIV infection 
Colony M of huCD4/huCCR5 CRFK were infected with HIV-AD8, a subtype B 
virus to test for the presence and functionality of the two receptors on the cell surface. 
The RT assay (Figure 21a) conducted post-transfection of 293T cells with AD8 plasmids 
prepped from different bacterial colonies shows strong positivity, indicative of virus 
production. The RT activity was monitored on Days 2, 4, and 5, all of which showed a 
positive signal. The signals of AD8 (1) and AD8 (3) increased by Day 5, whereas AD8 
(2) remained relatively unchanged from Day 4 (Figure 22a). The experiment was ended 
on Day 5, as there was a large amount of syncytia formation and the majority of the cell 
layer was obliterated (Figure 22c), whereas cell crowding is seen in the uninfected 
negative control (Figure 22b). 
a)     
 
Uninfected control       HIV-AD8 Infected control 
b)                   c)  
Figure 22. huCD4/huCCR5 C|RFK (Colony M) infection with HIVAD8. a) RT assay 
post-transfection of 293T cells and post-infection of huCD4/huCCR5 (Colony M) CRFK. 
(1), (2), and (3) are AD8 plasmids prepped from different colonies. Limited sequencing 
results (not shown) show that no nucleotide differences exist between the three colonies. 
b) Representative image of the uninfected negative control on Day 5. c) Representative 
image of syncytia formation on Day 5 taken from the AD8 (2) well. 
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3.5 Cell-to-cell fusion assay experiments to test HIV envelope interactions 
with CD4 and CCR5 derived from humans 
Fusion assays were developed by Eric Arts’ laboratory to test receptor-envelope 
interactions. In their version of the assay, a cell line already expressing huCD4 and 
huCCR5 is incubated with another cell line expressing the HIV envelope. The level of 
fusion between the two can be detected either utilizing the luciferase assay or the β-
galactosidase assay described in Section 2.11 of the Methods. In this project, the purpose 
of the assay was to test HIV envelope interactions with huCD4 and huCCR5, as well as 
feCD4 and feCCR5. Although cell lines expressing human CD4 and CCR5 were 
available, cell lines expressing feCD4 and feCCR5 was not available to us at first. To 
combat this, we instead sought to transfect the plasmids required for CD4 and CCR5 
expression alongside the pDM128fLuc plasmid required for the luciferase system into 
cells. These could then be incubated with cells expressing the envelope to test for fusion.  
As a proof-of-concept for the necessary three-plasmid transfection, 293T cells 
were triple-transfected with the huCD4, huCCR5, and pN1-GFP vectors to determine the 
level of triple-positivity using flow cytometry (Figure 23). Only ~7% of the GFP positive 
cells were double positive for CD4 and CCR5. Since 51.7% of live cells were GFP 
positive, only ~3.6% of the total live cells were triple-positive 
57  
 
 
 
Figure 23. Flow cytometry on 293T cells triple-transfected with pN1-GFP, huCD4 and 
huCCR5. Gating strategy: cell population → live cells → GFP positive cells → 
huCD4/huCCR5 positive cells. 
3.5.1 Triple transfection efficiency of 293T cells is too low to determine 
whether true receptor-envelope interactions are occurring when huCD4, 
huCCR5 and pDM128fLuc-transfected 293T are incubated with pREC-nfl-
HIV-transfected 293T  
The cell-to-cell fusion assay was conducted using 293T cells triple-transfected 
with the huCD4, huCCR5, and pDM128fLuc plasmid vectors. The pDM128fLuc plasmid 
encodes the luciferase gene whose expression is Rev and Tat dependent. The triple-
transfected 293T were incubated with 293T cells expressing HIV envelope from the 
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pREC-nfl-HIV plasmid. Several pREC-nfl-HIV plasmids were obtained from Arts Lab, 
where they were cloned. A total of 45 plasmids were screened by restriction digestion 
using SacI and SacII; 15 of these were positive.  
The HIV envelope expressed on the cell surface as a result of pREC-nfl-HIV 
transfection can mediate fusion with cell lines that expresses human CD4 and CCR5, 
upon being incubated with them, through receptor-envelope interactions. When cell-to-
cell fusion occurs, the HIV Tat and Rev proteins expressed from pREC-nfl-HIV drive 
expression of luciferase via pDM128fLuc. In this case, the triple-transfected 293T 
(transfected with the huCD4, huCCR5, and pDM128fLuc vectors) were mixed 293T 
expressing HIV envelope. Individual pREC-nfl-HIV, each expressing a distinct envelope 
variant, were used for transfections. The subtypes of these envelope are listed in Table 4. 
 
Table 4. List of all the IDs and the corresponding subtypes of the pREC-nfl-HIV 
plasmids. “U” indicates samples obtained from the Uganda cohort and “Z” indicates 
samples that were obtained from the Zimbabwe cohort. All the subtype B samples were 
obtained from American and Belgian cohorts. 
 
pREC-nfl-HIV  
plasmid ID 
Subtype 
B2 B 
B5 B 
B9 B 
B15 B 
Q0 B 
32U D 
38U A 
45U A 
82U A 
85U A 
42Z C 
95Z C 
 
As shown in Figure 24, a strong signal was observed in the positive control 
composed of cells where pDM128fLuc and pREC-nfl-HIV were co-transfected. 
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However, a positive signal was also seen in the negative control where triple-transfected 
cells were incubated with untransfected cells that do not express any envelope on their 
surface. A strong luminescence signal was also seen in the negative control where the 
cells triple-transfected with the plasmids for the receptors were incubated with the cells 
transfected with SG3∆env that contains a premature stop codon in env and thus should 
not express any envelope that could mediate fusion. Due to this, it can be concluded that 
the signals seen in the case of the test groups were not true positives and are a result of 
background level of luciferase activation. The proof-of-concept triple-transfection 
revealed that only ~3.6% of the cells could express the genes-of-interest from each 
plasmid. Thus, the lack of fusion seen here could be attributed to the scarcity of CD4 and 
CCR5 expression on the triple-transfected 293T cells. 
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Figure 24. Cell-to-cell fusion assay (luciferase system) of 293T triple-transfected with 
huCD4, huCCR5 and pDM128fLuc, incubated with 293T cells transfected with varying 
version of the pREC-nfl-HIV plasmid for HIV envelope expression. The notation under 
each bar indicates the two cell types that were incubated together. pDM128fLuc and 
pREC-nfl-HIV were transfected into the same cell as a positive control. SG3∆env is 
composed of the HIV backbone that contains a premature stop codon in env, thus the 
plasmid serves as a negative control. B2 through 95Z are distinct HIV strains with 
different envelope sequences. 
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3.5.2 The cell-to-cell fusion assay using luciferase detection produces high 
background luminescence  
As the prior experiment demonstrated that triple-transfection resulted in low CD4 
and CCR5 expression, the luciferase assay was repeated to test whether fusion is 
detectable in cells stably expressing the two receptors. The pDM128fLuc plasmid was 
transfected into either U87 or CRFK cells expressing human CD4 and CCR5, whereas the 
pREC-nfl-HIV plasmids were transfected into 293T cells. The U87.CD4.CCR5 and 
huCD4/huCCR5 CRFK were incubated with 293T expressing varying HIV envelope.  
In the fusion assays with these cells, a strong signal was detected in the positive 
controls where pREC-nfl-HIV and pDM128fLuc were co-transfected for both the 
receptor expressing cell lines (Figure 25). In the case of the U87.CD4.CCR5 cells, a 
positive luminescence signal, indicative of fusion with the 293T cells expressing the 
envelope of varying HIV subtypes (32U through Q0 in Figure 25), was higher than 
negative controls in which 293T cells were untransfected or transfected with a non-
functional envelope (SG3∆env). However, no drastic difference in luminescence was 
seen in these when compared to the negative controls (1.5-fold to less than 3-fold). 
The background level of luciferase expression for the negative control 
(untransfected 293T) was over five times higher with CRFK cells in comparison to the 
U87 cells. This trend is observed across all the samples, where huCD4/huCCR5 CRFK 
had higher overall levels of luciferase expression in comparison to the U87.CD4.CCR5 
cells. Luminescence levels for all treatments were similar for CRFK cells. Therefore, no 
conclusions can be drawn about whether the signal produced wherein the CRFK cells 
were incubated with 293T cells expressing HIV envelope was truly due to fusion or 
simply due to the background expression of luciferase. 
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Figure 25. Cell-to-cell fusion assay (luciferase system) of CRFK or U87 cells expressing 
human CD4 and CCR5 receptors, incubated with 293T cells transfected with a varying 
pREC-nfl- HIV plasmid for HIV envelope expression. The notation under each bar 
indicates the two cell types that were incubated together. The first listed transfection 
status under each bar is of the 293T cells (expressing HIV envelope from distinct pREC-
nfl-HIV) and the second listed transfection status is that of the CRFK/U87 CD4/CCR5 
cells (transfected with pDM128fLuc). The positive control is comprised of 
U87.CD4.CCR5 or CRFK.huCD4.huCCR5 cells that were co-transfected with pREC-nfl-
HIV and pDM128fLuc. Constructs 32U though Q0 indicate different pREC-nfl-HIV 
plasmids containing envelope sequences from different strains. 
3.5.3 The cell-to-cell fusion assay with β-galactosidase detection 
demonstrates human receptor-HIV envelope interactions  
Since the luciferase system produced a high background level of luminescence, 
the β-galactosidase system was adopted to test for the presence of receptor-envelope 
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interactions. U87.CD4.CCR5 and huCD4/huCCR5 CRFK cells were transfected with the 
ω plasmid of the β-galactosidase gene, whereas the 293T cells were transfected with a 
version of pREC-nfl-HIV, along with the α plasmid of the β-galactosidase gene. 
In the case of the U87.CD4.CCR5 cells, there was a significant difference 
between the luminescence level of the negative control (293Ts transfected with env 
mutant SG3∆env) and 293T cells expressing envelope from 32U, 38U, 95Z, B5 and B9 
(Figure 26a). This samples serve as a positive control for the fusion assay itself as we 
expect HIV envelope expressed on 293T to interact with human CD4 and CCR5 
expressed on U87 cells. This was shown by Weber et al. (2013)74.  
The novel aspect tested here was the functionality of the assay with CRFK cat 
cells expressing human CD4 and CCR5 receptors. As seen in Figure 26b, there was a 
significant difference between the luminescence level of the negative control (SG3∆env) 
and three subtype B Envs (B5, B9, Q0). The level of fusion, as quantified by the RLU, 
was much greater between the subtypes B Envs and huCD4/huCCR5 CRFK, than the 
subtypes B Envs and U87 cells. Although not statistically significant, there was an 
increase in the mean RLU of all three of the non-B subtypes when compared to SG3∆env. 
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b) huCD4/huCCR5 CRFK cells 
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Figure 26. Cell-to-cell fusion assay of CRFK cells and U87 cells expressing CD4 and 
CCR5 with 293T cells expressing a distinct strain variant of Env. The assay was done 
using the β-galactosidase system. The CD4/CCR5 receptor-expressing cell lines were 
transfected with the ω plasmid, whereas the 293T cells were transfected with the α 
plasmid in addition to pREC-nfl-HIV. The X-axis labels represent the plasmids that the 
293T cells were transfected with. a) U87.CD4.CCR5 fusion with 293T cells. b) 
huCD4/huCCR5 CRFK fusion with 293T cells. 
n=3. “*”, p<0.05; “**”, p<0.01; “***”, p<0.001. Error bars represent the standard error of 
the mean. A one-way ANOVA test followed by the Tuckey’s test was performed. 
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CHAPTER 4: DISCUSSION 
The long-term vision of this project is to establish a novel animal model whereby 
cats can be utilized to study HIV and develop vaccines and therapeutics against it. We are 
seeking to harness the similarities between HIV and FIV at the genetic level, as well as 
their comparable disease pathogenesis for our efforts. In particular, our aim is to generate 
FHIVenv chimeras (composed of HIV env inserted in the FIV backbone), that can infect 
and replicate in cats. Following this, therapeutics and vaccines targeting the HIV 
envelope can be tested in cats. The goal of this thesis was to lay the groundwork for this 
project, mainly through validating this concept in vitro. 
We attempted to make use of the yeast cloning system to make the plasmids 
needed to produce FHIVenv chimeric viruses. Prior to this, we first had to test whether 
the system could be used to clone the plasmids required to generate infectious FIV 
particles. The yeast cloning system was used to construct two plasmids – a cplt supplying 
the 5’ LTR, and the nfl supplying the remainder of the FIV genome, which were co- 
transfected to produce virus. We engineered these with the aim of eventually swapping 
the FIV env with HIV env in the nfl plasmid to make FHIVenvs. The FIV particles 
produced using this two-plasmid system were expected to have lower infectivity, as 
particles produced would contain either two copies of the nfl RNA, two copies of the cplt 
RNA, or a copy of each73. Infectious, replication-competent virus would only be 
produced in the third scenario, where both nfl and cplt are supplied. Thus, we expected 
longer infection periods and multiple passages on Gfox cells (which express CD134, the 
primary entry receptor for FIV) to see a positive signal on the RT assays of virus 
produced using the complementing system. We attempted to utilize several variations of 
the system including multiple passages of the virus on cells, cloning of the RRE into cplt 
and altering the ratio of nfl to complement. The rationale for using each of these is 
described in the Results.  
The last variation we attempted were virus spinoculations. This is a process 
whereby the virus and the cells to be infected are centrifuged for several hours to 
facilitate virus deposition, which forces virus attachment to the cell surface78. 
Spinoculations have been previously used successfully for infections of viruses such as 
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murine coronaviruses79, Herpes Simplex Virus 180, Hepatitis B Virus81, and HIV78. 
Additionally, spinoculations have also been shown to enhance FIV infection of 
monocyte-derived dendritic cells82. Thus, the protocol was utilized to infect Gfox cells 
with the virus produced from the ratio-controlled transfections of 293T cells with the nfl 
and cplt-rre plasmids. We found that FIV infectivity was enhanced in the positive control 
as positive RT activity was detected as early as Day 4 of the second passage (Figure 14). 
However, no such increase in activity was seen with the spinoculations of ratio-controlled 
nfl-6/cplt-rre viruses. Nevertheless, we were only able to observe weak RT activity from 
the FIV produced using the two-plasmid system. 
The yeast cloning system has been used successfully to generate vectors for 
transfections to produce infectious HIV73,83, as well as SHIV76. It has also been 
implemented to produce infectious FIV particles (Moghadasi, S.A., Arts, E.J, unpublished 
data). However, this has only been the case with the 34TF10 strain, and not the FIV-C36 
strain used here. Additionally, Sanger sequencing revealed several point mutations across 
the nfl vector. These mutations could have potentially resulted in decreasing the 
infectivity of the particles produced. 
In-fusion cloning was additionally attempted to clone the HIV envelope into the 
FIV backbone, however, either the backbone plasmid of FIV, or insert plasmid of HIV 
carried through across the cloning reaction steps. This was the case even after gel 
extracting the PCR amplified fragments of either of the two and treating the product with 
DpnI, which should cleave any methylated DNA, thereby cleaving any carry-through 
plasmid. Several other strategies and modifications could be tested in the future that were 
not tested herein due to time constraints. Gibson cloning is a potential strategy that can be 
pursued84. The In-fusion cloning kit should not pose any issues with cloning large 
vectors; however, part of the issue here was PCR amplifying the large backbone around 
the FIV plasmid. The In-fusion cloning reaction should work with multiple fragments as 
well. A strategy can be implemented wherein the FIV plasmid is amplified as two 
separate fragments with the overlapping regions needed for In-fusion cloning. 
In addition to generating infectious virus, another major aim of this project was to 
generate cat cell lines expressing human CD4 and CCR5, as well as feline CD4 and 
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CCR5, in order to test HIV Envelope and CD4/CCR5 receptor interactions through 
infections and fusion assays. CRFK cells were utilized as they are adherent, robust, and 
relatively transfectable. 
Single-positive cell lines were generated to express either feCD4 or feCCR5. 
Colony 9, the colony with the greatest level of feCCR5 expression was used for 
transfections with feCD4 to generate double positive cell lines. However, only 8.6% of 
the total live cells of Colony 2O were positive for feCD4 and feCCR5, and this was the 
colony with the highest percentage of double-positive cells. This was the case even after 
several passages in double-drug (puromycin and hygromycin) media. To ensure that the 
feCD4 gene was in fact being expressed, RNA isolation using Trizol extraction was 
conducted 48 hours post- transfection of CRFK. This was DNase treated and used for 
cDNA synthesis, followed by PCR amplification with primers specific for the feCD4 
gene. Results revealed that feCD4 was amplified, and the transfection was indeed 
successful (data not shown). feCD4 expression was also supported by the result that up to 
52.7% of the cells in Colony 3 of feCD4 CRFK were positive for the receptor. 
One possible explanation for obtaining a low level of feCD4/feCCR5 expression 
could be poor initial transfection efficiency of pBABE.feCD4 into the feCCR5 CRFK cell 
line. Another reason for this could be that the single colonies that were initially picked 
and grown for screening were low-expressors for feCD4 to begin with. Even after several 
passages in selection media, the level of feCD4 that the colony initially expressed would 
have remain unchanged, i.e., survival in drug-containing media would not necessarily 
guarantee high expression of feCD4 on the surface. To obtain a population with a higher 
level of double expression, Colony 3 of feCD4 CRFK, which was most positive for 
feCD4 by flow cytometry, could be transfected with the pBABE.feCCR5 plasmid. 
Furthermore, several colonies throughout these cell line generation experiments grew 
well in drug-containing media but showed poor expression of either receptors when 
screened by flow cytometry, indicating that the poor expressors were still acclimating to 
grow in the selection media. These colonies were passaged for up to 10 weeks before 
being screened. To avoid pursuing these colonies, flow cytometry can be conducted 
earlier in the process to eliminate any colonies that are low-expressors to begin with. 
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Only the colonies that demonstrate moderate to high expression can be grown and 
passaged, and re-screened by flow cytometry prior to sorting to achieve a pure 
population. 
We successfully generated a huCD4/huCCR5 CRFK cell line in this project, 
which we pursued further for the cell-to-cell fusion assay as well an infectivity assay. The 
fusion assay has only been conducted using 293T cells and U87.CD4.CCR5 cells74,75 in 
the past at the Arts Lab. Therefore, it was an important proof-of-concept experiment to 
demonstrate that the assay can be conducted using CRFK cells that stably express CD4 
and CCR5 receptors. The luciferase system of cell-to-cell fusion assay produced too high 
background luciferase expression. Following this, the β-galactosidase system was 
implemented. 
As seen in Figure 26, cell-to-cell fusion occurred in the case of huCD4/huCCR5 
CRFK cells, as is the case with U87.CD4.CCR5 cells. There was a significant increase in 
mean RLU in all three of the non-B subtypes tested, and two of the subtypes B Envs 
tested in the case of the U87.CD4.CCR5 cells. In the case of the huCD4/huCCR5 CRFK, 
there was a significant increase in RLU of all the subtype B Envs. Although not 
significant, there was an increase in the mean RLU of the three non-B subtypes Envs, 
when compared to the negative control where SG3∆env was transfected. Interestingly, the 
level of fusion seen between the CRFK cells and subtype B Envs is a lot greater than the 
level of fusion seen between the U87 cells and subtype B and non-B Envs. Platt et al. 
(1997) have demonstrated that in cases where there is high-level expression of CD4, a 
low level of CCR5 is enough to obtain maximal infection. In cases where CD4 expression 
is low, a larger quantity of CCR5 is needed for maximal infection with macrophage-
tropic HIV-185. In contrast to this, Alexander et al. (2010) have demonstrated that in 
subtype C variants, high levels of CD4 and CCR5 are required for virus entry, and a 
decline in CCR5 was accompanied with a reduction in entry86. Lastly, Etemad et al. 
(2009) demonstrated that chronic subtype A Envs have an increased ability to replicate in 
cells with low CCR5 expression87. Although not much is known about the level of 
expression of either receptors on the cell surface of U87 cells, CD4 expression on the 
CRFKs is higher than CCR5, as seen in the flow cytometry performed post-sorting 
(Figure 20). This is most likely because the most positive huCD4-expressing CRFK 
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colony was used for huCCR5 transfections. If this is the case, it could potentially explain 
why Q0 Env, whose envelope is derived from a chronic virus, is able to fuse more 
efficiently with the CRFK cells. 
 
This fusion assay was conducted using feCD4/feCCR5 (Colony 2O), however, 
fusion was found to not occur (data not shown). This does not necessarily indicate that 
HIV envelope cannot bind to feline CD4 and CCR5. Much like in the case of triple-
transfection of 293T cells (Figure 23), the lack of fusion events can most likely be 
attributed to the scarcity of feCD4/feCCR5 double-positive cells. We did discover that the 
CCR5 antibody that is cross reactive for human, mouse, and rat CCR5 was able to bind 
and detect feline CCR5 in the flow cytometry experiments, which could potentially be 
due to the sequence similarity of human and feline CCR5. It would therefore be plausible 
for HIV envelope to be able to bind feline receptors. In the future, the most positive 
feCD4 CRFK cell colony, Colony 3, can be used for transfections with feCCR5 to 
produce a cell line with higher double positivity. 
 
The huCD4/huCCR5 CRFK (colony M) further demonstrated receptor positivity 
in infection experiments (Figure 22), where infection with HIV-AD8 resulted in strong, 
positive RT activity. The assay demonstrated that the RT activity of AD8 (1) and AD3 (3) 
increased on Day 5, whereas the activity of AD8 (2) remained relatively unchanged, as its 
signal is similar to that of Day 4. Munk et al. (2007) conducted a similar experiment 
where HIV-1NL-BaL was used to infect CRFK expressing human CD4 and CCR5
88. 
Although capable of a first-round of infection (evident due to syncytia formation), no 
spreading infection was seen, as indicated by p24 ELISA levels equivalent to background 
levels. They attributed this lack of spreading to certain types of feline APOBEC3, 
including APOBEC3H and APOBEC3CH, which were packaged into the released virus 
particles, and elicited their effects by introducing G→A mutations in reverse-transcribed 
intermediates in the second round of infection. HIV Vif typically counteracts human 
APOBEC3, however, it is incapable of countering feline APOBEC3 similarly. Therefore, 
the RT positivity could be a result of the first round of AD8-HIV infection. Interestingly, 
they found syncytia formation on Day 3-4 of infection, but continued to monitor p24 
levels by ELISA up to Day 12. Our experiment ended by Day 5, where we saw syncytia 
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formation, but the majority of the cell layer was destroyed, and so the virus had to be 
harvested. Part of this obliteration could be due to starting with too high of a virus input. 
Munk et al. (2007) infected their huCD4/huCCR5 CRFK with a low Multiplicity of 
Infection (MOI) of 0.05 to evaluate multiple cycles of infection. MOI is the ratio of virus 
to cells. The lack of difference seen between Day 4 and Day 5 of AD8 (2) infection in our 
case could be attributed to a halt of spread seen after the first round of infection. Although 
we did not control for MOI, it would be of interest to begin with a low MOI virus to 
infect huCD4/huCCR5 CRFK with HIV-AD8 and monitor this by RT assays with 
supernatants past Day 5 to see if RT activity decreases due to the halting of secondary 
spreading caused by feline APOBEC3. Nevertheless, the occurrence of any infection at 
all gave us confidence in the receptor expression of huCD4/huCCR5 on the CRFK cells. 
Overall, our long-term mission is to generate a novel animal model whereby cats 
can be used to study HIV. The goal of this thesis was to establish the foundation for this 
project by making the FHIVenvs and cell lines required for the in vitro experiments. 
Although the yeast cloning and in-fusion cloning strategies were ineffective, alternative 
cloning strategies can be implemented to generate the FHIVenv chimeras. We 
successfully generated a huCD4/huCCR5 CRFK cell line expressing high levels of the 
two receptors. Although a feCD4/feCCR5 CRFK cell line was engineered, it only had 
low-level feCD4 expression. A cell line that has a greater level of feCD4 expression can 
be engineered using some of the strategies described above. Following this, cell-to-cell 
fusion assays can be conducted with the diverse pREC-nfl-HIV to isolate HIV envelopes 
that can utilize feline CD4/CCR5 to enter and infect cat cells. These HIV envs can be 
cloned into the FIVC-36 backbone, following which they can be used for infectivity 
assays with the CD4/CCR5-expressing CRFK cell lines to isolate the FHIVenvs capable 
of replicating in cat cells in vitro. These can then be pursued for in vivo infection of cats. 
Overall, if successful, this project will allow for cats to be used as model organisms to 
test therapeutics and vaccines that target the HIV envelope. Their cost-effectiveness and 
suitability make cats good candidates for this purpose. 
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